Delivered-To: arianne@mdnewsline.com
Received: by 2002:a02:9717:0:b0:574:c484:26af with SMTP id x23csp4054876jai;
        Mon, 13 Oct 2025 07:37:55 -0700 (PDT)
X-Google-Smtp-Source: AGHT+IGzpz4Y4/61rgPt84hJg26S89wFh5H8oiWqo5Cp5kTI6pLpA+vVTHoxj8oKK6A+ppxGOOZV
X-Received: by 2002:ac8:5fc2:0:b0:4e7:224d:30a1 with SMTP id d75a77b69052e-4e7224d3119mr65640761cf.66.1760366274871;
        Mon, 13 Oct 2025 07:37:54 -0700 (PDT)
ARC-Seal: i=1; a=rsa-sha256; t=1760366274; cv=none;
        d=google.com; s=arc-20240605;
        b=l24j+zaNu/HJ8IbebNyVpcs2m4H+KWbspbviUWt6jRcH+UpW2/E7Ngb3G0j6Zjpdya
         limQb+2B4oEraSAYwSn5cruhqyoyRXSc82DByHKc4f8leXKxP3d7yfHwnSN8gGyvjp3J
         Xrovi6pJbP4bLvkphz5hQZTJQA6AhSpZhxKmDq4Klzvl7+kTVJ6Mimv7/hsBOwesU1H6
         Fa5o8rVtpFFIMSS4xGk5XMSe6bxnkh0tH9+BSz21UDkCMASsHmhGw+9+S6X4yPCM31Nj
         rDjA9VJbmbhkY3p+zR5abj7aiRG7nfSf0AeiAC3gO1ClBFM09+xcX0l3fTLCWyLvj6R0
         43Wg==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605;
        h=list-unsubscribe-post:list-unsubscribe:mime-version:subject:to
         :reply-to:from:date:message-id:dkim-signature:dkim-signature;
        bh=BRu4EEFRQC3C1CgBjzXJHvZ+pkLH15pwybt6X+BTZuA=;
        fh=3xB+MLBDTvc9o7V6yk6MXbnRNcWccTbqJULCKNfokKc=;
        b=l3clcCKp114QQ1S9si3tANkI57HnnfU+x/QJgOx4cx/mD5wml+APkBaSLCA794lL+P
         JiKvo/QheOBjF+bKo7XaH2nRIV4LXo42OEx/4cMGzfd4oCekriLccVaUuKWNDJnwxMxQ
         AFjHA0mjUIMA5tJtS8x75TESZL/NEmYlQs74hx9IUHxemfKLse8vpFzfaXvkJWUdiEnr
         T1xLFNDg5sR+Ptk4XI99FF18R09eLHLVQAJWCPhvUOixDd672LmLbap2BAA9qKCy+YIn
         LfVccXLLNsFpI4Gq1iOXXHsF9PEQ+ZuCF5IE22dSbL1lVeNomH0c2rZhf3OviEzaa5t1
         jq7g==;
        dara=google.com
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@mdnewsline.com header.s=ctct1 header.b=cBkMDluX;
       dkim=pass header.i=@auth.ccsend.com header.s=1000073432 header.b=JEV5FZRi;
       spf=pass (google.com: domain of aap05a6/ntmysqq/cm0mv+q==_1133406273203_ioxhggsaeekcqojkyihwmw==@in.constantcontact.com designates 208.75.123.250 as permitted sender) smtp.mailfrom="AAp05a6/NTMySqq/cM0mv+Q==_1133406273203_IOXhGGsaEeKCQojkYIhwmw==@in.constantcontact.com";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=mdnewsline.com
Return-Path: <AAp05a6/NTMySqq/cM0mv+Q==_1133406273203_IOXhGGsaEeKCQojkYIhwmw==@in.constantcontact.com>
Received: from ccm37.constantcontact.com (ccm37.constantcontact.com. [208.75.123.250])
        by mx.google.com with ESMTPS id d75a77b69052e-4e70702c435si48311391cf.368.2025.10.13.07.37.54
        for <arianne@mdnewsline.com>
        (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256);
        Mon, 13 Oct 2025 07:37:54 -0700 (PDT)
Received-SPF: pass (google.com: domain of aap05a6/ntmysqq/cm0mv+q==_1133406273203_ioxhggsaeekcqojkyihwmw==@in.constantcontact.com designates 208.75.123.250 as permitted sender) client-ip=208.75.123.250;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@mdnewsline.com header.s=ctct1 header.b=cBkMDluX;
       dkim=pass header.i=@auth.ccsend.com header.s=1000073432 header.b=JEV5FZRi;
       spf=pass (google.com: domain of aap05a6/ntmysqq/cm0mv+q==_1133406273203_ioxhggsaeekcqojkyihwmw==@in.constantcontact.com designates 208.75.123.250 as permitted sender) smtp.mailfrom="AAp05a6/NTMySqq/cM0mv+Q==_1133406273203_IOXhGGsaEeKCQojkYIhwmw==@in.constantcontact.com";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=mdnewsline.com
DKIM-Signature: v=1; q=dns/txt; a=rsa-sha256; c=relaxed/relaxed; s=ctct1; d=mdnewsline.com; h=date:mime-version:subject:X-Feedback-ID:X-250ok-CID:message-id:from:reply-to:list-unsubscribe:list-unsubscribe-post:to; bh=BRu4EEFRQC3C1CgBjzXJHvZ+pkLH15pwybt6X+BTZuA=; b=cBkMDluXTnmBnX305ZVffaBv51UQfV5zn7QBmcrgsyhKWiZifwJFgdB5MTyPk7My1SBtZLGNaYyW09StidKSFSTrAIUNSVwU/8x+YsZbe2QxY+j1sFvRv+67fsiKy021XeV1NuA4XTKncVVkLb9CUXMwb2vtJlLEkkREavixopqyxNWWBmsjF4VDpNTGKu+TAQeeEDEA9PhWanHzaqhth2YjeocB6XyDqdYOtiZSKsUsPLHtyUsKrqkk9Ki6qFNx1TzVbYkGXHyipt+wT4TNSsiNfQQxT37Ly6CPxhvBHLPtrlhgCZMw/CQ+xyE2kSLpRFWZpUST5yguqaE+fLAuLw==
DKIM-Signature: v=1; q=dns/txt; a=rsa-sha256; c=relaxed/relaxed; s=1000073432; d=auth.ccsend.com; h=date:mime-version:subject:X-Feedback-ID:X-250ok-CID:message-id:from:reply-to:list-unsubscribe:list-unsubscribe-post:to; bh=BRu4EEFRQC3C1CgBjzXJHvZ+pkLH15pwybt6X+BTZuA=; b=JEV5FZRiTuC+Zoe3Ux8dfShMc5JzwZQ1dLrgFtvFKzLnGkxOtjMLjzQj/G9I5GOtxn30iKk3fmpkxYkm8L44Mxv+UQ0oZQpigKE+TjgZXSp2HxQKtDUMv8cvELff7htMWZcJbooK2R3PzKeJcpf3rptbKVWyw9OJ0H5ZkZ+yQzQ=
Message-ID: <1142279041717.1133406273203.-1.0.1971037JL.2001@synd.ccsend.com>
Date: Mon, 13 Oct 2025 10:37:54 -0400 (EDT)
From: MD Newsline <info@mdnewsline.com>
Reply-To: info@mdnewsline.com
To: arianne@mdnewsline.com
Subject: NOW APPROVED: Administration in just minutes is an option
MIME-Version: 1.0
Content-Type: multipart/alternative; 
	boundary="----=_Part_79869416_238998003.1760366274476"
List-Unsubscribe: <https://visitor.constantcontact.com/do?p=un&m=001ShN7CepJUKDGWfhQJgbAsA%3D%3D&se=001TAeZDpsMR68%3D&t=001EkZLEx15CcE%3D&llr=tvpoes4ab>
List-Unsubscribe-Post: List-Unsubscribe=One-Click
X-Campaign-Activity-ID: 029d396b-afcd-4ccc-92aa-afdc3349aff9
X-250ok-CID: 029d396b-afcd-4ccc-92aa-afdc3349aff9
X-Channel-ID: 20e5e118-6b1a-11e2-8242-88e46088709b
X-Return-Path-Hint: AAp05a6/NTMySqq/cM0mv+Q==_1133406273203_IOXhGGsaEeKCQojkYIhwmw==@in.constantcontact.com
X-Roving-Campaignid: 1142279041717
X-Roving-Id: 1133406273203.-1
X-Feedback-ID: 20e5e118-6b1a-11e2-8242-88e46088709b:029d396b-afcd-4ccc-92aa-afdc3349aff9:1133406273203:CTCT
X-CTCT-ID: 20e5e118-6b1a-11e2-8242-88e46088709b
X-Gm-Original-To: arianne@mdnewsline.com

------=_Part_79869416_238998003.1760366274476
Content-Type: text/plain; charset=utf-8
Content-Transfer-Encoding: quoted-printable

%%[SET @subscriberkey =3D _subscriberKey]%% %%[SET @content =3D emailname_ =
JobID]%% %%[SET @compkey =3D AttributeValue("Composite Key")]%% ContentBloc=
kbyId("260486")  =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =
=E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C %%=3Dv(@PreHeader)=3D%% NOW APPROVED KEYTRUDA QLEX is approve=
d for use in adult patients across most solid tumor indications for KEYTRUD=
A=C2=AE (=E2=80=8Dpembrolizumab=E2=80=8D) Injection 100 mg=E2=80=94whether =
alone or in combination with other therapies One such indication for KEYTRU=
DA and KEYTRUDA QLEX is the adjuvant treatment of adult patients with renal=
 cell carcinoma (=E2=80=8DRCC=E2=80=8D) at intermediate-high or high risk o=
f recurrence following nephrectomy, or following nephrectomy and resection =
of metastatic lesions. Selected Safety Information Contraindications KEYTRU=
DA QLEX is contraindicated in patients with known hypersensitivity to berah=
yaluronidase alfa, hyaluronidase or to any of its excipients. Severe and Fa=
tal Immune-Mediated Adverse Reactions =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX =
are monoclonal antibodies that belong to a class of drugs that bind to eith=
er the programmed death receptor-1 (=E2=80=8DPD=E2=80=8D-=E2=80=8D1=E2=80=
=8D) or the programmed death ligand 1 (=E2=80=8DPD=E2=80=8D-=E2=80=8DL1=E2=
=80=8D), blocking the PD=E2=80=8D-=E2=80=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=
=E2=80=8DL1 pathway, thereby removing inhibition of the immune response, po=
tentially breaking peripheral tolerance and inducing immune-mediated advers=
e reactions. Immune-mediated adverse reactions, which may be severe or fata=
l, can occur in any organ system or tissue, can affect more than one body s=
ystem simultaneously, and can occur at any time after starting treatment or=
 after discontinuation of treatment. Important immune-mediated adverse reac=
tions listed here may not include all possible severe and fatal immune-medi=
ated adverse reactions. Expand to See Selected Safety Information =E2=80=A2=
 Monitor patients closely for symptoms and signs that may be clinical manif=
estations of underlying immune-mediated adverse reactions. Early identifica=
tion and management are essential to ensure safe use of anti=E2=80=8D=E2=80=
=93=E2=80=8DPD=E2=80=8D-=E2=80=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=E2=80=8DL=
1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at b=
aseline and periodically during treatment. In cases of suspected immune-med=
iated adverse reactions, initiate appropriate workup to exclude alternative=
 etiologies, including infection. Institute medical management promptly, in=
cluding specialty consultation as appropriate. =E2=80=A2 Withhold or perman=
ently discontinue KEYTRUDA and KEYTRUDA QLEX depending on severity of the i=
mmune-mediated adverse reaction. In general, if KEYTRUDA and KEYTRUDA QLEX =
require interruption or discontinuation, administer systemic corticosteroid=
 therapy (=E2=80=8D1 to 2 mg=E2=80=8D/=E2=80=8Dkg=E2=80=8D/=E2=80=8Dday pre=
dnisone or equivalent=E2=80=8D) until improvement to Grade 1 or less. Upon =
improvement to Grade 1 or less, initiate corticosteroid taper and continue =
to taper over at least 1 month. Consider administration of other systemic i=
mmunosuppressants in patients whose adverse reactions are not controlled wi=
th corticosteroid therapy. Collapse Selected Safety Information continues b=
elow. Patients have the option to switch from KEYTRUDA to KEYTRUDA QLEX=E2=
=80=94or KEYTRUDA QLEX to KEYTRUDA=E2=80=94at their next scheduled dose For=
 certain patients, treatment with KEYTRUDA QLEX offers flexibility by not r=
equiring an infusion chair     Selected Safety Information (=E2=80=8Dcontin=
ued=E2=80=8D) Severe and Fatal Immune-Mediated Adverse Reactions (=E2=80=8D=
continued=E2=80=8D) =E2=80=A2 Monitor patients closely for symptoms and sig=
ns that may be clinical manifestations of underlying immune-mediated advers=
e reactions. Early identification and management are essential to ensure sa=
fe use of anti=E2=80=8D=E2=80=93=E2=80=8DPD=E2=80=8D-=E2=80=8D1=E2=80=8D/=
=E2=80=8DPD=E2=80=8D-=E2=80=8DL1 treatments. Evaluate liver enzymes, creati=
nine, and thyroid function at baseline and periodically during treatment. I=
n cases of suspected immune-mediated adverse reactions, initiate appropriat=
e workup to exclude alternative etiologies, including infection. Institute =
medical management promptly, including specialty consultation as appropriat=
e. =E2=80=A2 Withhold or permanently discontinue KEYTRUDA and KEYTRUDA QLEX=
 depending on severity of the immune-mediated adverse reaction. In general,=
 if KEYTRUDA and KEYTRUDA QLEX require interruption or discontinuation, adm=
inister systemic corticosteroid therapy (=E2=80=8D1 to 2 mg=E2=80=8D/=E2=80=
=8Dkg=E2=80=8D/=E2=80=8Dday prednisone or equivalent=E2=80=8D) until improv=
ement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate cor=
ticosteroid taper and continue to taper over at least 1 month. Consider adm=
inistration of other systemic immunosuppressants in patients whose adverse =
reactions are not controlled with corticosteroid therapy. Immune-Mediated P=
neumonitis =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated p=
neumonitis. The incidence is higher in patients who have received prior tho=
racic radiation. Immune-mediated pneumonitis occurred in 3.4% (=E2=80=8D94/=
2799=E2=80=8D) of patients receiving KEYTRUDA, including fatal (=E2=80=8D0.=
1%=E2=80=8D), Grade 4 (=E2=80=8D0.3%=E2=80=8D), Grade 3 (=E2=80=8D0.9%=E2=
=80=8D), and Grade 2 (=E2=80=8D1.3%=E2=80=8D) reactions. Systemic corticost=
eroids were required in 67% (=E2=80=8D63/94=E2=80=8D) of patients. Pneumoni=
tis led to permanent discontinuation of KEYTRUDA in 1.3% (=E2=80=8D36=E2=80=
=8D) and withholding in 0.9% (=E2=80=8D26=E2=80=8D) of patients. All patien=
ts who were withheld reinitiated KEYTRUDA after symptom improvement; of the=
se, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients. Imm=
une-mediated pneumonitis occurred in 5% (=E2=80=8D13/251=E2=80=8D) of patie=
nts receiving KEYTRUDA QLEX in combination with chemotherapy, including fat=
al (=E2=80=8D0.4%=E2=80=8D), Grade 3 (=E2=80=8D2%=E2=80=8D), and Grade 2 (=
=E2=80=8D1.2%=E2=80=8D) adverse reactions. Severe and Fatal Immune-Mediated=
 Adverse Reactions (=E2=80=8Dcontinued=E2=80=8D) =E2=80=A2 Monitor patients=
 closely for symptoms and signs that may be clinical manifestations of unde=
rlying immune-mediated adverse reactions. Early identification and manageme=
nt are essential to ensure safe use of anti=E2=80=8D=E2=80=93=E2=80=8DPD=E2=
=80=8D-=E2=80=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=E2=80=8DL1 treatments. Eva=
luate liver enzymes, creatinine, and thyroid function at baseline and perio=
dically during treatment. In cases of suspected immune-mediated adverse rea=
ctions, initiate appropriate workup to exclude alternative etiologies, incl=
uding infection. Institute medical management promptly, including specialty=
 consultation as appropriate. =E2=80=A2 Withhold or permanently discontinue=
 KEYTRUDA and KEYTRUDA QLEX depending on severity of the immune-mediated ad=
verse reaction. In general, if KEYTRUDA and KEYTRUDA QLEX require interrupt=
ion or discontinuation, administer systemic corticosteroid therapy (=E2=80=
=8D1 to 2 mg=E2=80=8D/=E2=80=8Dkg=E2=80=8D/=E2=80=8Dday prednisone or equiv=
alent=E2=80=8D) until improvement to Grade 1 or less. Upon improvement to G=
rade 1 or less, initiate corticosteroid taper and continue to taper over at=
 least 1 month. Consider administration of other systemic immunosuppressant=
s in patients whose adverse reactions are not controlled with corticosteroi=
d therapy. Immune-Mediated Pneumonitis =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX=
 can cause immune-mediated pneumonitis. The incidence is higher in patients=
 who have received prior thoracic radiation. Immune-mediated pneumonitis oc=
curred in 3.4% (=E2=80=8D94/2799=E2=80=8D) of patients receiving KEYTRUDA, =
including fatal (=E2=80=8D0.1%=E2=80=8D), Grade 4 (=E2=80=8D0.3%=E2=80=8D),=
 Grade 3 (=E2=80=8D0.9%=E2=80=8D), and Grade 2 (=E2=80=8D1.3%=E2=80=8D) rea=
ctions. Systemic corticosteroids were required in 67% (=E2=80=8D63/94=E2=80=
=8D) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA =
in 1.3% (=E2=80=8D36=E2=80=8D) and withholding in 0.9% (=E2=80=8D26=E2=80=
=8D) of patients. All patients who were withheld reinitiated KEYTRUDA after=
 symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in=
 59% of the 94 patients. Immune-mediated pneumonitis occurred in 5% (=E2=80=
=8D13/251=E2=80=8D) of patients receiving KEYTRUDA QLEX in combination with=
 chemotherapy, including fatal (=E2=80=8D0.4%=E2=80=8D), Grade 3 (=E2=80=8D=
2%=E2=80=8D), and Grade 2 (=E2=80=8D1.2%=E2=80=8D) adverse reactions. Immun=
e-Mediated Colitis =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX can cause immune-me=
diated colitis, which may present with diarrhea. Cytomegalovirus infection/=
reactivation has been reported in patients with corticosteroid-refractory i=
mmune-mediated colitis. In cases of corticosteroid-refractory colitis, cons=
ider repeating infectious workup to exclude alternative etiologies. =E2=80=
=A2 Immune-mediated colitis occurred in 1.7% (=E2=80=8D48/2799=E2=80=8D) of=
 patients receiving KEYTRUDA, including Grade 4 (=E2=80=8D<=E2=80=8D0.1%=E2=
=80=8D), Grade 3 (=E2=80=8D1.1%=E2=80=8D), and Grade 2 (=E2=80=8D0.4%=E2=80=
=8D) reactions. Systemic corticosteroids were required in 69% (=E2=80=8D33/=
48=E2=80=8D); additional immunosuppressant therapy was required in 4.2% of =
patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (=E2=
=80=8D15=E2=80=8D) and withholding in 0.5% (=E2=80=8D13=E2=80=8D) of patien=
ts. All patients who were withheld reinitiated KEYTRUDA after symptom impro=
vement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 pat=
ients. Immune-mediated colitis occurred in 1.2% (=E2=80=8D3/251=E2=80=8D) o=
f patients receiving KEYTRUDA QLEX in combination with chemotherapy, includ=
ing Grade 3 (=E2=80=8D0.8%=E2=80=8D) and Grade 2 (=E2=80=8D0.4%=E2=80=8D) a=
dverse reactions. Hepatotoxicity and Immune-Mediated Hepatitis =E2=80=A2 KE=
YTRUDA and KEYTRUDA QLEX can cause immune-mediated hepatitis. Immune-mediat=
ed hepatitis occurred in 0.7% (=E2=80=8D19/2799=E2=80=8D) of patients recei=
ving KEYTRUDA, including Grade 4 (=E2=80=8D<=E2=80=8D0.1%=E2=80=8D), Grade =
3 (=E2=80=8D0.4%=E2=80=8D), and Grade 2 (=E2=80=8D0.1%=E2=80=8D) reactions.=
 Systemic corticosteroids were required in 68% (=E2=80=8D13/19=E2=80=8D) of=
 patients; additional immunosuppressant therapy was required in 11% of pati=
ents. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (=E2=
=80=8D6=E2=80=8D) and withholding in 0.3% (=E2=80=8D9=E2=80=8D) of patients=
. All patients who were withheld reinitiated KEYTRUDA after symptom improve=
ment; of these, none had recurrence. Hepatitis resolved in 79% of the 19 pa=
tients. Immune-mediated hepatitis occurred in 0.4% (=E2=80=8D1/251=E2=80=8D=
) of patients receiving KEYTRUDA QLEX in combination with chemotherapy, inc=
luding Grade 2 (=E2=80=8D0.4%=E2=80=8D) adverse reactions. Immune-Mediated =
Endocrinopathies Adrenal Insufficiency =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX=
 can cause primary or secondary adrenal insufficiency. For Grade 2 or highe=
r, initiate symptomatic treatment, including hormone replacement as clinica=
lly indicated. Withhold KEYTRUDA and KEYTRUDA QLEX depending on severity. A=
drenal insufficiency occurred in 0.8% (=E2=80=8D22/2799=E2=80=8D) of patien=
ts receiving KEYTRUDA, including Grade 4 (=E2=80=8D<=E2=80=8D0.1%=E2=80=8D)=
, Grade 3 (=E2=80=8D0.3%=E2=80=8D), and Grade 2 (=E2=80=8D0.3%=E2=80=8D) re=
actions. Systemic corticosteroids were required in 77% (=E2=80=8D17/22=E2=
=80=8D) of patients; of these, the majority remained on systemic corticoste=
roids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA i=
n <=E2=80=8D0.1% (=E2=80=8D1=E2=80=8D) and withholding in 0.3% (=E2=80=8D8=
=E2=80=8D) of patients. All patients who were withheld reinitiated KEYTRUDA=
 after symptom improvement. Adrenal insufficiency occurred in 2% (=E2=80=8D=
5/251=E2=80=8D) of patients receiving KEYTRUDA QLEX in combination with che=
motherapy, including Grade 3 (=E2=80=8D0.4%=E2=80=8D) and Grade 2 (=E2=80=
=8D0.8%=E2=80=8D) adverse reactions. Hypophysitis =E2=80=A2 KEYTRUDA and KE=
YTRUDA QLEX can cause immune-mediated hypophysitis. Hypophysitis can presen=
t with acute symptoms associated with mass effect such as headache, photoph=
obia, or visual field defects. Hypophysitis can cause hypopituitarism. Init=
iate hormone replacement as indicated. Withhold or permanently discontinue =
KEYTRUDA and KEYTRUDA QLEX depending on severity. =E2=80=A2 Hypophysitis oc=
curred in 0.6% (=E2=80=8D17/2799=E2=80=8D) of patients receiving KEYTRUDA, =
including Grade 4 (=E2=80=8D<=E2=80=8D0.1%=E2=80=8D), Grade 3 (=E2=80=8D0.3=
%=E2=80=8D), and Grade 2 (=E2=80=8D0.2%=E2=80=8D) reactions. Systemic corti=
costeroids were required in 94% (=E2=80=8D16/17=E2=80=8D) of patients; of t=
hese, the majority remained on systemic corticosteroids. Hypophysitis led t=
o permanent discontinuation of KEYTRUDA in 0.1% (=E2=80=8D4=E2=80=8D) and w=
ithholding in 0.3% (=E2=80=8D7=E2=80=8D) of patients. All patients who were=
 withheld reinitiated KEYTRUDA after symptom improvement. Thyroid Disorders=
 =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated thyroid dis=
orders. Thyroiditis can present with or without endocrinopathy. Hypothyroid=
ism can follow hyperthyroidism. Initiate hormone replacement for hypothyroi=
dism or institute medical management of hyperthyroidism as clinically indic=
ated. Withhold or permanently discontinue KEYTRUDA and KEYTRUDA QLEX depend=
ing on severity. =E2=80=A2 Thyroiditis occurred in 0.6% (=E2=80=8D16/2799=
=E2=80=8D) of patients receiving KEYTRUDA, including Grade 2 (=E2=80=8D0.3%=
=E2=80=8D). None discontinued, but KEYTRUDA was withheld in <=E2=80=8D0.1% =
(=E2=80=8D1=E2=80=8D) of patients. =E2=80=A2 Hyperthyroidism occurred in 3.=
4% (=E2=80=8D96/2799=E2=80=8D) of patients receiving KEYTRUDA, including Gr=
ade 3 (=E2=80=8D0.1%=E2=80=8D) and Grade 2 (=E2=80=8D0.8%=E2=80=8D). It led=
 to permanent discontinuation of KEYTRUDA in <=E2=80=8D0.1% (=E2=80=8D2=E2=
=80=8D) and withholding in 0.3% (=E2=80=8D7=E2=80=8D) of patients. All pati=
ents who were withheld reinitiated KEYTRUDA after symptom improvement. Hypo=
thyroidism occurred in 8% (=E2=80=8D237/2799=E2=80=8D) of patients receivin=
g KEYTRUDA, including Grade 3 (=E2=80=8D0.1%=E2=80=8D) and Grade 2 (=E2=80=
=8D6.2%=E2=80=8D). It led to permanent discontinuation of KEYTRUDA in <=E2=
=80=8D0.1% (=E2=80=8D1=E2=80=8D) and withholding in 0.5% (=E2=80=8D14=E2=80=
=8D) of patients. All patients who were withheld reinitiated KEYTRUDA after=
 symptom improvement. The majority of patients with hypothyroidism required=
 long-term thyroid hormone replacement. =E2=80=A2 Thyroiditis occurred in 0=
.4% (=E2=80=8D1/251=E2=80=8D) of patients receiving KEYTRUDA QLEX in combin=
ation with chemotherapy, including Grade 2 (=E2=80=8D0.4%=E2=80=8D). Hypert=
hyroidism occurred in 8% (=E2=80=8D20/251=E2=80=8D) of patients receiving K=
EYTRUDA QLEX in combination with chemotherapy, including Grade 2 (=E2=80=8D=
3.2%=E2=80=8D). Hypothyroidism occurred in 14% (=E2=80=8D35/251=E2=80=8D) o=
f patients receiving KEYTRUDA QLEX in combination with chemotherapy, includ=
ing Grade 2 (=E2=80=8D11%=E2=80=8D). Type 1 Diabetes Mellitus (=E2=80=8DDM=
=E2=80=8D), Which Can Present With Diabetic Ketoacidosis =E2=80=A2 Monitor =
patients for hyperglycemia or other signs and symptoms of diabetes. Initiat=
e treatment with insulin as clinically indicated. Withhold KEYTRUDA and KEY=
TRUDA QLEX depending on severity. Type 1 DM occurred in 0.2% (=E2=80=8D6/27=
99=E2=80=8D) of patients receiving KEYTRUDA. It led to permanent discontinu=
ation in <=E2=80=8D0.1% (=E2=80=8D1=E2=80=8D) and withholding of KEYTRUDA i=
n <=E2=80=8D0.1% (=E2=80=8D1=E2=80=8D) of patients. All patients who were w=
ithheld reinitiated KEYTRUDA after symptom improvement. Type 1 diabetes mel=
litus occurred in 0.4% (=E2=80=8D1/251=E2=80=8D) of patients receiving KEYT=
RUDA QLEX in combination with chemotherapy. Immune-Mediated Nephritis With =
Renal Dysfunction =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX can cause immune-med=
iated nephritis. =E2=80=A2 Immune-mediated nephritis occurred in 0.3% (=E2=
=80=8D9/2799=E2=80=8D) of patients receiving KEYTRUDA, including Grade 4 (=
=E2=80=8D<=E2=80=8D0.1%=E2=80=8D), Grade 3 (=E2=80=8D0.1%=E2=80=8D), and Gr=
ade 2 (=E2=80=8D0.1%=E2=80=8D) reactions. Systemic corticosteroids were req=
uired in 89% (=E2=80=8D8/9=E2=80=8D) of patients. Nephritis led to permanen=
t discontinuation of KEYTRUDA in 0.1% (=E2=80=8D3=E2=80=8D) and withholding=
 in 0.1% (=E2=80=8D3=E2=80=8D) of patients. All patients who were withheld =
reinitiated KEYTRUDA after symptom improvement; of these, none had recurren=
ce. Nephritis resolved in 56% of the 9 patients. Immune-Mediated Dermatolog=
ic Adverse Reactions =E2=80=A2 KEYTRUDA and KEYTRUDA QLEX can cause immune-=
mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-John=
son syndrome, drug rash with eosinophilia and systemic symptoms, and toxic =
epidermal necrolysis, has occurred with anti=E2=80=8D=E2=80=93=E2=80=8DPD=
=E2=80=8D-=E2=80=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=E2=80=8DL1 treatments. =
Topical emollients and/or topical corticosteroids may be adequate to treat =
mild to moderate nonexfoliative rashes. Withhold or permanently discontinue=
 KEYTRUDA and KEYTRUDA QLEX depending on severity. =E2=80=A2 Immune-mediate=
d dermatologic adverse reactions occurred in 1.4% (=E2=80=8D38/2799=E2=80=
=8D) of patients receiving KEYTRUDA, including Grade 3 (=E2=80=8D1%=E2=80=
=8D) and Grade 2 (=E2=80=8D0.1%=E2=80=8D) reactions. Systemic corticosteroi=
ds were required in 40% (=E2=80=8D15/38=E2=80=8D) of patients. These reacti=
ons led to permanent discontinuation in 0.1% (=E2=80=8D2=E2=80=8D) and with=
holding of KEYTRUDA in 0.6% (=E2=80=8D16=E2=80=8D) of patients. All patient=
s who were withheld reinitiated KEYTRUDA after symptom improvement; of thes=
e, 6% had recurrence. The reactions resolved in 79% of the 38 patients. Imm=
une-mediated dermatologic adverse reactions occurred in 1.6% (=E2=80=8D4/25=
1=E2=80=8D) of patients receiving KEYTRUDA QLEX in combination with chemoth=
erapy, including Grade 4 (=E2=80=8D0.8%=E2=80=8D) and Grade 3 (=E2=80=8D0.8=
%=E2=80=8D) adverse reactions. Other Immune-Mediated Adverse Reactions =E2=
=80=A2 The following clinically significant immune-mediated adverse reactio=
ns occurred at an incidence of <=E2=80=8D1% (=E2=80=8Dunless otherwise note=
d=E2=80=8D) in patients who received KEYTRUDA, KEYTRUDA QLEX, or were repor=
ted with the use of other anti=E2=80=8D=E2=80=93=E2=80=8DPD=E2=80=8D-=E2=80=
=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=E2=80=8DL1 treatments. Severe or fatal =
cases have been reported for some of these adverse reactions. Cardiac/Vascu=
lar: Myocarditis, pericarditis, vasculitis; Nervous System: Meningitis, enc=
ephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravi=
s (=E2=80=8Dincluding exacerbation=E2=80=8D), Guillain-Barr=C3=A9 syndrome,=
 nerve paresis, autoimmune neuropathy; Ocular: Uveitis, iritis and other oc=
ular inflammatory toxicities can occur. Some cases can be associated with r=
etinal detachment. Various grades of visual impairment, including blindness=
, can occur. If uveitis occurs in combination with other immune-mediated ad=
verse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may=
 require treatment with systemic steroids to reduce the risk of permanent v=
ision loss; Gastrointestinal: Pancreatitis, to include increases in serum a=
mylase and lipase levels, gastritis (=E2=80=8D2.8%=E2=80=8D), duodenitis; M=
usculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis=
 (=E2=80=8Dand associated sequelae, including renal failure=E2=80=8D), arth=
ritis (=E2=80=8D1.5%=E2=80=8D), polymyalgia rheumatica; Endocrine: Hypopara=
thyroidism; Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophag=
ocytic lymphohistiocytosis, systemic inflammatory response syndrome, histio=
cytic necrotizing lymphadenitis (=E2=80=8DKikuchi lymphadenitis=E2=80=8D), =
sarcoidosis, immune thrombocytopenic purpura, solid organ transplant reject=
ion, other transplant (=E2=80=8Dincluding corneal graft=E2=80=8D) rejection=
. Hypersensitivity and Infusion- or Administration-Related Reactions =E2=80=
=A2 KEYTRUDA and KEYTRUDA QLEX can cause severe or life-threatening adminis=
tration-related reactions, including hypersensitivity and anaphylaxis. With=
 KEYTRUDA and KEYTRUDA QLEX, monitor for signs and symptoms of infusion- an=
d administration-related systemic reactions including rigors, chills, wheez=
ing, pruritus, flushing, rash, hypotension, hypoxemia, and fever. Infusion-=
related reactions have been reported in 0.2% of 2799 patients receiving KEY=
TRUDA. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reacti=
ons. For Grade 3 or Grade 4 reactions, stop infusion and permanently discon=
tinue KEYTRUDA. Hypersensitivity and administration-related systemic reacti=
ons occurred in 3.2% (=E2=80=8D8/251=E2=80=8D) of patients receiving KEYTRU=
DA QLEX in combination with platinum doublet chemotherapy, including Grade =
2 (=E2=80=8D2.8%=E2=80=8D). Interrupt injection (=E2=80=8Dif not already fu=
lly administered=E2=80=8D) and resume if symptoms resolve for mild or moder=
ate systemic reactions. For severe or life-threatening systemic reactions, =
stop injection and permanently discontinue KEYTRUDA QLEX. Complications of =
Allogeneic Hematopoietic Stem Cell Transplantation (=E2=80=8DHSCT=E2=80=8D)=
 =E2=80=A2 Fatal and other serious complications can occur in patients who =
receive allogeneic HSCT before or after anti=E2=80=8D=E2=80=93=E2=80=8DPD=
=E2=80=8D-=E2=80=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=E2=80=8DL1 treatments. =
Transplant-related complications include hyperacute graft-versus-host disea=
se (=E2=80=8DGVHD=E2=80=8D), acute and chronic GVHD, hepatic veno-occlusive=
 disease after reduced intensity conditioning, and steroid-requiring febril=
e syndrome (=E2=80=8Dwithout an identified infectious cause=E2=80=8D). Thes=
e complications may occur despite intervening therapy between anti=E2=80=8D=
=E2=80=93=E2=80=8DPD=E2=80=8D-=E2=80=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=E2=
=80=8DL1 treatments and allogeneic HSCT. Follow patients closely for eviden=
ce of these complications and intervene promptly. Consider the benefit vs r=
isks of using anti=E2=80=8D=E2=80=93=E2=80=8DPD=E2=80=8D-=E2=80=8D1=E2=80=
=8D/=E2=80=8DPD=E2=80=8D-=E2=80=8DL1 treatments prior to or after an alloge=
neic HSCT. Increased Mortality in Patients With Multiple Myeloma =E2=80=A2 =
In trials in patients with multiple myeloma, the addition of KEYTRUDA to a =
thalidomide analogue plus dexamethasone resulted in increased mortality. Tr=
eatment of these patients with an anti=E2=80=8D=E2=80=93=E2=80=8DPD=E2=80=
=8D-=E2=80=8D1=E2=80=8D/=E2=80=8DPD=E2=80=8D-=E2=80=8DL1 treatment in this =
combination is not recommended outside of controlled trials. Embryofetal To=
xicity =E2=80=A2 Based on their mechanism of action, KEYTRUDA and KEYTRUDA =
QLEX can each cause fetal harm when administered to a pregnant woman. Advis=
e women of this potential risk. In females of reproductive potential, verif=
y pregnancy status prior to initiating KEYTRUDA or KEYTRUDA QLEX and advise=
 them to use effective contraception during treatment and for 4 months afte=
r the last dose. Adverse Reactions =E2=80=A2 In study MK-347A-D77, when KEY=
TRUDA QLEX was administered with chemotherapy in metastatic non=E2=80=8D=E2=
=80=93=E2=80=8Dsmall cell lung cancer (=E2=80=8DNSCLC=E2=80=8D), serious ad=
verse reactions occurred in 39% of patients. Serious adverse reactions in =
=E2=89=A5=E2=80=8D1% of patients who received KEYTRUDA QLEX were pneumonia =
(=E2=80=8D10%=E2=80=8D), thrombocytopenia (=E2=80=8D4%=E2=80=8D), febrile n=
eutropenia (=E2=80=8D4%=E2=80=8D), neutropenia (=E2=80=8D2.8%=E2=80=8D), mu=
sculoskeletal pain (=E2=80=8D2%=E2=80=8D), pneumonitis (=E2=80=8D2%=E2=80=
=8D), diarrhea (=E2=80=8D1.6%=E2=80=8D), rash (=E2=80=8D1.2%=E2=80=8D), res=
piratory failure (=E2=80=8D1.2%=E2=80=8D), and anemia (=E2=80=8D1.2%=E2=80=
=8D). Fatal adverse reactions occurred in 10% of patients including pneumon=
ia (=E2=80=8D3.2%=E2=80=8D), neutropenic sepsis (=E2=80=8D2%=E2=80=8D), dea=
th not otherwise specified (=E2=80=8D1.6%=E2=80=8D), respiratory failure (=
=E2=80=8D1.2%=E2=80=8D), parotitis (=E2=80=8D0.4%=E2=80=8D), pneumonitis (=
=E2=80=8D0.4%=E2=80=8D), pneumothorax (=E2=80=8D0.4%=E2=80=8D), pulmonary e=
mbolism (=E2=80=8D0.4%=E2=80=8D), neutropenic colitis (=E2=80=8D0.4%=E2=80=
=8D), and seizure (=E2=80=8D0.4%=E2=80=8D). KEYTRUDA QLEX was permanently d=
iscontinued due to an adverse reaction in 16% of 251 patients. Adverse reac=
tions which resulted in permanent discontinuation of KEYTRUDA QLEX in =E2=
=89=A5=E2=80=8D2% of patients included pneumonia and pneumonitis. Dosage in=
terruptions of KEYTRUDA QLEX due to an adverse reaction occurred in 45% of =
patients. Adverse reactions which required dosage interruption in =E2=89=A5=
=E2=80=8D2% of patients included neutropenia, anemia, thrombocytopenia, pne=
umonia, rash, and increased aspartate aminotransferase. The most common adv=
erse reactions (=E2=80=8D=E2=89=A5=E2=80=8D20%=E2=80=8D) were nausea (=E2=
=80=8D25%=E2=80=8D), fatigue (=E2=80=8D25%=E2=80=8D), and musculoskeletal p=
ain (=E2=80=8D21%=E2=80=8D). =E2=80=A2 In KEYNOTE-564, when KEYTRUDA was ad=
ministered as a single agent for the adjuvant treatment of renal cell carci=
noma, serious adverse reactions occurred in 20% of patients receiving KEYTR=
UDA; the serious adverse reactions (=E2=80=8D=E2=89=A5=E2=80=8D1%=E2=80=8D)=
 were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and d=
iabetic ketoacidosis (=E2=80=8D1% each=E2=80=8D). Fatal adverse reactions o=
ccurred in 0.2% including 1 case of pneumonia. Discontinuation of KEYTRUDA =
due to adverse reactions occurred in 21% of 488 patients; the most common (=
=E2=80=8D=E2=89=A5=E2=80=8D1%=E2=80=8D) were increased alanine aminotransfe=
rase (=E2=80=8DALT=E2=80=8D) (=E2=80=8D1.6%=E2=80=8D), colitis (=E2=80=8D1%=
=E2=80=8D), and adrenal insufficiency (=E2=80=8D1%=E2=80=8D). The most comm=
on adverse reactions (=E2=80=8D=E2=89=A5=E2=80=8D20%=E2=80=8D) were musculo=
skeletal pain (=E2=80=8D41%=E2=80=8D), fatigue (=E2=80=8D40%=E2=80=8D), ras=
h (=E2=80=8D30%=E2=80=8D), diarrhea (=E2=80=8D27%=E2=80=8D), pruritus (=E2=
=80=8D23%=E2=80=8D), and hypothyroidism (=E2=80=8D21%=E2=80=8D). Lactation =
=E2=80=A2 Because of the potential for serious adverse reactions in breastf=
ed children, advise women not to breastfeed during treatment and for 4 mont=
hs after the last dose. Before prescribing KEYTRUDA or KEYTRUDA QLEX, pleas=
e read the accompanying Prescribing Information for KEYTRUDA and KEYTRUDA Q=
LEX. The Medication Guides for KEYTRUDA and KEYTRUDA QLEX also are availabl=
e.       keytrudahcp.com      Ask Merck      Learn About The Merck Access P=
rogram >      Learn About Merck Oncology Patient Support >    For prescribe=
rs: please click here for state-required price disclosures.   Note: This me=
ssage was distributed from an email account used for sending messages only.=
 Please do not reply to this message. This email communication is from Merc=
k Sharp & Dohme LLC. Please manage your email preferences or unsubscribe an=
ytime by clicking here. If you have trouble accessing this link, please sen=
d an email to merck_privacy_office@merck.com with a subject line of Email O=
pt-Out Request =E2=80=93 US=E2=80=8D-=E2=80=8DPDS=E2=80=8D-=E2=80=8D00=E2=
=80=8D02=E2=80=8D4.   Copyright =C2=A9 2025 Merck & Co., Inc., Rahway, NJ, =
USA and its affiliates. All rights reserved. To learn more about Merck=E2=
=80=99s commitment to privacy and your rights, please visit merck.com/priva=
cy.   Merck Privacy Office, 351 N Sumneytown Pike, UG4B-24, North Wales, PA=
 19454, USA US=E2=80=8D-=E2=80=8DPDS=E2=80=8D-=E2=80=8D0=E2=80=8D00=E2=80=
=8D24 10=E2=80=8D/=E2=80=8D25 MD Newsline | 222 W Merchandise Mart Plaza, #=
1212, Chicago, IL 60654 Unsubscribe Update Profile | Constant Contact Data =
Notice Sent by info@mdnewsline.com powered by Try email marketing for free =
today!
------=_Part_79869416_238998003.1760366274476
Content-Type: text/html; charset=utf-8
Content-Transfer-Encoding: quoted-printable

<html style=3D"word-break: break-word; mso-hyphenate: none;"><body style=3D=
"word-break: break-word; mso-hyphenate: none;">
=09=09

=09=09

=09=09%%[SET @subscriberkey =3D _subscriberKey]%%
%%[SET @content =3D emailname_ JobID]%%
%%[SET @compkey =3D AttributeValue("Composite Key")]%%
<!DOCTYPE html>
<html xmlns=3D"http://www.w3.org/1999/xhtml" xmlns:v=3D"urn:schemas-microso=
ft-com:vml" xmlns:o=3D"urn:schemas-microsoft-com:office:office" style=3D"wo=
rd-break: break-word; mso-hyphenate: none;">
<head>
ContentBlockbyId("260486")
<meta charset=3D"UTF-8">
<meta name=3D"x-apple-disable-message-reformatting">
<meta name=3D"viewport" content=3D"width=3Ddevice-width, initial-scale=3D1,=
 maximum-scale=3D1, minimum-scale=3D1, user-scalable=3Dno">
<meta content=3D"IE=3Dedge">
<meta name=3D"format-detection" content=3D"telephone=3Dno">
<meta name=3D"format-detection" content=3D"date=3Dno">
<meta name=3D"format-detection" content=3D"address=3Dno">
<meta name=3D"format-detection" content=3D"email=3Dno">
<!--[if IE]><style>body,table,p,td,th,ul,li,div,span {mso-line-height-rule:=
 exactly !important;} sup, sub {font-size: 80% !important;display: inline !=
important;line-height: 1em !important;vertical-align: top !important;} sub =
{vertical-align: bottom !important;} .outlook-wrap-all {word-break:break-al=
l !important;}</style><![endif]-->
<!--[if mso]><style>table, td {  mso-table-lspace: 0pt; mso-table-rspace: 0=
pt; } .height_mob{mso-height: auto !important;}</style><![endif]-->
<!--[if gte mso 12]><style>sup, sub {font-size: 100% !important;vertical-al=
ign: top !important;display: inline !important;} sub {mso-text-raise: -0.15=
em;}  sup {mso-text-raise: 0.15em;} </style><![endif]-->
<!--[if gte mso 9]><style>li {text-indent: -1em; text-align:-webkit-match-p=
arent; display:list-item;} } </style><![endif]-->
<style>
@media screen and (max-width: 599px),
yahoo and (max-width: 480px),
print and (max-width: 552px) {
  * {
    box-sizing: border-box;
    -webkit-text-size-adjust: none;
    text-size-adjust: none;
  }

  html,
body {
    width: 100vw;
  }

  body {
    margin: 0px !important;
    padding: 0px !important;
    font-family: Arial, Helvetica, sans-serif;
    color: #58595B;
  }

  .device_width,
.brand_cell,
.preheader_cell,
.footer_cell,
.ves_cell,
.merckconnect_cell {
    width: 100% !important;
    display: table;
  }

  .veeva_header img,
.header img,
.main_body img,
.mobile_settings img {
    display: inline-block !important;
    margin-bottom: 0;
    vertical-align: middle;
  }

  .display_block img {
    display: block !important;
  }

  .display_block img.mobile_img {
    display: block !important;
    height: auto;
  }

  .image_mobile img.desktop_img {
    display: none !important;
  }

  .veeva_header .columns .image,
.header .columns .image,
.main_body .columns .image {
    text-align: center;
    vertical-align: middle;
  }

  .reference p {
    line-height: 1em !important;
  }

  .columns th {
    width: 100% !important;
    display: block !important;
  }

  .columns_mobile .column__parent {
    height: 20px !important;
  }

  .columns_mobile .cell {
    height: auto !important;
  }

  .columns_mobile td table {
    width: 100% !important;
    height: 100%;
  }

  th.cell {
    height: inherit !important;
  }

  .image__width--100 img,
.mobile__width--100,
.column__width--100 {
    width: 100% !important;
  }

  .mobile__align--left {
    text-align: left !important;
  }

  .mobile__align--center {
    text-align: center !important;
  }

  .mobile__align--right {
    text-align: right !important;
  }

  .pdlr20 {
    padding-left: 20px !important;
    padding-right: 20px !important;
  }

  .pdlr0 {
    padding-left: 0px !important;
    padding-right: 0px !important;
  }

  #Kinetic:checked~* .height_mob {
    height: 526px;
  }

  #slide0:checked+table .height_mob {
    height: 526px;
  }

  .lnht20 {
    height: 20px !important;
    font-size: 20px !important;
    line-height: 20px !important;
  }
}
</style>
<style>
@media screen and (max-width:736px),
yahoo and (max-width:480px),
print and (max-width:552px) {
  .device_width {
    width: 100% !important;
    display: table;
  }

  #Kinetic:checked~* .interactive {
    display: block !important;
  }
}
</style>
<style type=3D"text/css">
@media yahoo, only screen and (min-width:0) {
  body[yahoo] .mj-accordion-element {
    display: block;
  }

  #Kinetic:checked~* .staticacc {
    display: block !important;
  }

  input.mj-accordion-checkbox,
.mj-accordion-less {
    display: none !important;
  }

  input.mj-accordion-checkbox+* .mj-accordion-title {
    touch-action: manipulation;
    -webkit-user-select: none;
    -moz-user-select: none;
    user-select: none;
  }

  input.mj-accordion-checkbox+* .mj-accordion-content {
    overflow: hidden;
    display: none;
  }

  input.mj-accordion-checkbox+* .mj-accordion-more {
    display: block !important;
  }

  input.mj-accordion-checkbox:checked+* .mj-accordion-content {
    display: block;
  }

  input.mj-accordion-checkbox:checked+* .mj-accordion-expand {
    display: none;
  }

  input.mj-accordion-checkbox:checked+* .mj-accordion-more {
    display: none !important;
  }

  input.mj-accordion-checkbox:checked+* .mj-accordion-less {
    display: block !important;
  }
}
</style>
<style>
@media yahoo, only screen and (min-width:0) {
  #Kinetic:checked~* .incTab {
    display: inline-block !important;
  }

  #Kinetic:checked~* .interactive {
    display: block !important;
  }

  #slide0:checked+table .slide2-content {
    display: none;
  }

  #slide0:checked+table .slide3-content {
    display: none;
  }

  #Kinetic:checked~* .height_mob {
    height: 526px;
  }

  #slideSSI:checked+table .outerSSI {
    display: block !important;
  }

  #slide0:checked+table .height_mob {
    height: 526px;
  }

  #Kinetic:checked~* .lnht42 {
    height: 42px !important;
    font-size: 42px !important;
    line-height: 42px !important;
  }

  #Kinetic:checked~* .cardspace {
    display: block !important;
  }
}
@media screen and (max-width:736px),
yahoo and (max-width:480px),
print and (max-width:552px) {
  #CarouselWrapper,
.CarouselMain {
    width: 100% !important;
  }

  .slide1-content,
.slide2-content,
.slide3-content {
    top: 0px;
    width: 100% !important;
    background-repeat: no-repeat;
    font-size: 20px;
    line-height: 25px;
    font-family: Arial, Helvetica, sans-serif;
  }

  .mob_align {
    vertical-align: text-bottom;
  }

  .padding_right {
    padding-right: 5px !important;
  }

  .mobilebg {
    background-image: url('https://www.us-hh.com/Email/Keytruda/US-PDS-0002=
4/now-approved-bar-mobile.png') !important;
  }

  .mobilebg2 {
    background-image: url('https://www.us-hh.com/Email/Keytruda/US-PDS-0002=
4/Card-Header-Bar-Mobile.png') !important;
  }

  .mobilebg3 {
    background-image: url('https://www.us-hh.com/Email/Keytruda/US-PDS-0002=
4/grad-border-mob.jpg') !important;
  }

  .d-none {
    display: none !important;
  }

  .mobi-block {
    display: block !important;
  }

  .h-auto {
    height: auto !important;
  }

  .d-inline {
    display: inline !important;
  }

  #slide0:checked+table .height_mob {
    height: 610px !important;
  }

  .mob-pad45 {
    padding: 20px 33px 20px 33px !important;
  }

  .pdlr18 {
    padding-left: 18px !important;
    padding-right: 18px !important;
  }

  #slide0:checked+table .pdB20card2 {
    padding-bottom: 20px !important;
  }

  .pdb20 {
    padding-bottom: 20px !important;
  }

  .pd395mg,
.pd790mg {
    padding-left: 8px !important;
    padding-right: 8px !important;
  }

  .pd-SSI {
    padding: 0px 45px 0px 45px !important;
  }

  .pd-SSI2 {
    padding-left: 45px !important;
    padding-right: 45px !important;
  }

  .pd-card1 {
    padding: 18px 35px 18px 35px !important;
  }

  .pd-card2 {
    padding: 18px 15px 18px 15px !important;
  }

  .pd-card3 {
    padding: 18px 44px 18px 44px !important;
  }

  #Kinetic:checked~* .lnht42 {
    height: 20px !important;
    font-size: 20px !important;
    line-height: 20px !important;
  }

  .pd-card2-txt2 {
    padding: 0px 51px 0px 51px !important;
  }

  .pd-card2-txt1 {
    padding: 0px 40px 10px 40px !important;
  }

  .pd-rccadj {
    padding: 18px 45px 8px 45px !important;
  }
}
@media (min-width: 369px) and (max-width: 374px) {
  .mob-pad8 {
    padding-left: 8px !important;
    padding-right: 8px !important;
  }
}
@media only screen and (max-width: 368px) {
  #slide0:checked+table .height_mob {
    height: 637px !important;
  }

  .mob-pad8 {
    padding-left: 8px !important;
    padding-right: 8px !important;
  }
}
</style>
<style>
@media yahoo {
  .button {
    line-height: 50px !important;
  }
}
</style>



 =20
  <style data-name=3D"interactive" data-ignore-inlining>
#Kinetic:checked~* .interactive {
  display: block !important;
}
#Kinetic:checked~* .& .interactive {
  display: none !important;
}
</style>

<!--[if gte mso 9]>
<xml>


96

</xml><![endif]-->
<style>
@media print {
  #_two50 {
    background-image: url('https://2merck.everestengagement.com/ea/rL7XYGpn=
kw/?t=3Dp&e=3D%%_SubscriberKey%%&c=3D%%=3Dv(@compkey)=3D%%');
  }
}
</style>


<style>@media only screen and (max-width:480px) {
  .footer-main-width {
    width: 100% !important;
  }
  .footer-mobile-hidden {
    display: none !important;
  }
  .footer-column {
    display: block !important;
  }
  .footer-mobile-stack {
    display: block !important;
  }
  .footer-mobile-stack-padding {
    padding-top: 3px;
  }
}</style></head>
<body bgcolor=3D"#FFFFFF" style=3D"word-break: break-word; mso-hyphenate: n=
one; padding: 0; margin: 0px;">
    <!--[if !mso]><!-->
   =20
    <!--<![endif]-->
    <div style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text=
-size-adjust: none; -ms-text-size-adjust: none; display: none; font-size: 1=
px; color: #333333; line-height: 1px; max-height: 0px; max-width: 0px; opac=
ity: 0; overflow: hidden;"></div>
    <div style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text=
-size-adjust: none; -ms-text-size-adjust: none; display: none; max-height: =
0px; overflow: hidden;">&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nb=
sp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;=
&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zw=
nj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;=
&nbsp;&zwnj;</div>
    <table class=3D"wrapper" width=3D"100%" height=3D"100%" cellspacing=3D"=
0" cellpadding=3D"0" border=3D"0" align=3D"center" style=3D"word-break: bre=
ak-word; mso-hyphenate: none; mso-table-lspace: 0pt; mso-table-rspace: 0pt;=
 min-width: 100%; min-height: 100%; background-color: #FFFFFF;" bgcolor=3D"=
#FFFFFF">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
      <tr style=3D"word-break: break-word; mso-hyphenate: none;">
        <td class=3D"topPadding" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding-top: 30px; padding-bottom: 30px;" align=3D"center">
          <center style=3D"word-break: break-word; mso-hyphenate: none;">
            <table class=3D"above_header device_width" width=3D"660" cellsp=
acing=3D"0" cellpadding=3D"0" border=3D"0" align=3D"center" style=3D"word-b=
reak: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; mso-table-rsp=
ace: 0pt; margin: 0 auto;">
              <tbody style=3D"word-break: break-word; mso-hyphenate: none;"=
>
                <tr style=3D"word-break: break-word; mso-hyphenate: none;">
                  <td class=3D"layout columns" style=3D"word-break: break-w=
ord; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adj=
ust: none; padding: 0px 0px 0px 0px; background-color: #ffffff;" bgcolor=3D=
"#ffffff">
                    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"=
0" border=3D"0" style=3D"word-break: break-word; mso-hyphenate: none; mso-t=
able-lspace: 0pt; mso-table-rspace: 0pt;">
                      <tbody style=3D"word-break: break-word; mso-hyphenate=
: none;">
                        <tr style=3D"word-break: break-word; mso-hyphenate:=
 none;">
                          <th class=3D"device_width cell preheader" align=
=3D"left" valign=3D"top" height=3D"13" style=3D"mso-hyphenate: none; width:=
 600px; height: 13px; padding: 16px 20px 10px 20px; word-break: break-word;=
 font-weight: normal;" width=3D"600">
                            <p style=3D"word-break: break-word; mso-hyphena=
te: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; font-=
family: Arial, Helvetica, sans-serif; font-size: 11px; line-height: 13.2px;=
 text-align: left; color: #58595B; margin: 0;">
                              <span style=3D"word-break: break-word; mso-hy=
phenate: none; font-family: Arial,  Helvetica,  sans-serif;">%%=3Dv(@PreHea=
der)=3D%%</span>
                            </p>
                          </th>
                        </tr>
                      </tbody>
                    </table>
                  </td>
                </tr>
              </tbody>
            </table>
           =20
<table class=3D"main_body device_width" width=3D"660" cellspacing=3D"0" cel=
lpadding=3D"0" border=3D"0" align=3D"center" style=3D"word-break: break-wor=
d; mso-hyphenate: none; mso-table-lspace: 0pt; mso-table-rspace: 0pt; margi=
n: 0 auto; background-color: #ffffff;" bgcolor=3D"#ffffff">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">

    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"layout columns" valign=3D"top" style=3D"word-break: break-=
word; mso-hyphenate: none; font-weight: normal; border-bottom: 6px solid #6=
CC04A; background-color: #7C02BB;" bgcolor=3D"#7C02BB">
    <table width=3D"100%" class=3D"mobilebg" cellspacing=3D"0" cellpadding=
=3D"0" border=3D"0" valign=3D"top" style=3D"word-break: break-word; mso-hyp=
henate: none; mso-table-lspace: 0pt; mso-table-rspace: 0pt; background-colo=
r: #7C02BB; background-image: url('https://www.us-hh.com/Email/Keytruda/US-=
PDS-00024/now-approved-bar-desktop.png'); background-position: center cente=
r; background-repeat: no-repeat; background-size: 100% 100%;" bgcolor=3D"#7=
C02BB" background=3D"https://www.us-hh.com/Email/Keytruda/US-PDS-00024/now-=
approved-bar-desktop.png">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"column__parent device_width" style=3D"word-break: break-wo=
rd; mso-hyphenate: none; width: 660px; font-weight: normal;" width=3D"660">
<!--[if gte mso 9]>
<v:rect xmlns:v=3D"urn:schemas-microsoft-com:vml" fill=3D"true" stroke=3D"f=
alse" style=3D"width:660px;height:94px;padding:0px 20px 0px 20px; align:cen=
ter;margin:0 auto;">
<v:fill type=3D"frame" src=3D"https://www.us-hh.com/Email/Keytruda/US-PDS-0=
0024/now-approved-bar-desktop.png" />
<v:textbox inset=3D"0,0,0,0">
<![endif]-->
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
valign=3D"top" style=3D"word-break: break-word; mso-hyphenate: none; mso-ta=
ble-lspace: 0pt; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-=
size-adjust: none; -ms-text-size-adjust: none; padding: 0px 0px 0px 0px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell" align=3D"center" valign=3D"middle" styl=
e=3D"mso-hyphenate: none; padding: 33px 0px 32px 0px; word-break: break-wor=
d; font-weight: normal;">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 25px; text-align: center; color: #ffffff; margin: =
0; text-align: center;">NOW APPROVED</p>
    </th>
    </tr>

    </table>
    </td>
    </tr>
    </table>
    <!--[if gte mso 9]>
    </v:textbox>
    </v:rect>
    <![endif]-->
    </th>
    </tr>
    </table>
    </th>
    </tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
  <td class=3D"layout columns" align=3D"center" style=3D"word-break: break-=
word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-ad=
just: none;">
    <table width=3D"100%" cellspacing=3D"0" align=3D"center" cellpadding=3D=
"0" border=3D"0" style=3D"word-break: break-word; mso-hyphenate: none; mso-=
table-lspace: 0pt; mso-table-rspace: 0pt; margin: 0 auto;">
      <tr style=3D"word-break: break-word; mso-hyphenate: none;">
        <td class=3D"cell display_block mobile__align--center h-auto" align=
=3D"center" valign=3D"top" style=3D"word-break: break-word; mso-hyphenate: =
none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; width: 66=
0px; padding: 25px 0; margin: 0 auto; text-align: center;" width=3D"660">
          <img class src=3D"https://www.us-hh.com/Email/Keytruda/US-PDS-000=
24/keytruda-qlex-logo.png" title alt=3D"image" width=3D"281" border=3D"0" s=
tyle=3D"word-break: break-word; mso-hyphenate: none; border: 0; display: bl=
ock; max-width: 100%; font-size: 5px; line-height: 5px; color: #58595B; tex=
t-align: center; margin: 0 auto;">

        </td>
      </tr>
    </table>
  </td>
</tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; bac=
kground-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
bgcolor=3D"#F1F1F1" style=3D"word-break: break-word; mso-hyphenate: none; m=
so-table-lspace: 0pt; mso-table-rspace: 0pt; background-color: #F1F1F1;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_headline pdlr20" align=3D"left" vali=
gn=3D"top" style=3D"mso-hyphenate: none; width: 620px; padding: 20px 20px 2=
0px 20px; word-break: break-word; font-weight: normal; border-top: 2px soli=
d #7C02BB;" width=3D"620">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"t=
op" style=3D"mso-hyphenate: none; width: 580px; padding: 20px 20px 20px 20p=
x; word-break: break-word; font-weight: normal; background-color: #ffffff; =
border: 1px solid #808285;" width=3D"580" bgcolor=3D"#ffffff">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">

    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"=
mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: =
none; word-break: break-word; font-weight: normal; font-family: Arial, Helv=
etica, sans-serif; padding-bottom: 20px;">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 18px; line-height: 22px; text-align: left; color: =
#58595B; margin: 0;">
    <strong style=3D"word-break: break-word; mso-hyphenate: none; font-fami=
ly: Arial,  Helvetica,  sans-serif; color: #58595B;">
      <span style=3D"word-break: break-word; mso-hyphenate: none; color: #4=
49C44;">KEYTRUDA </span><span style=3D"word-break: break-word; mso-hyphenat=
e: none; color: #7C02BB;">QLEX</span> is approved for use in adult patients=
 across most solid tumor indications for <span style=3D"word-break: break-w=
ord; mso-hyphenate: none; color: #449C44;">KEYTRUDA<sup style=3D"word-break=
: break-word; mso-hyphenate: none; font-size: 12px; mso-text-raise: 0px; li=
ne-height: 0px;">&reg;</sup></span> <span style=3D"word-break: break-word; =
mso-hyphenate: none; color: #449C44;">(&zwj;pembrolizumab&zwj;)</span> Inje=
ction 100 mg&mdash;whether alone or in combination with other therapies
    </strong></p>
    </td>
    </tr>
       <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"=
mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: =
none; word-break: break-word; font-weight: normal; font-family: Arial, Helv=
etica, sans-serif;">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 16px; text-align: left; color: #58595B; margin: 0;=
">
One such indication for KEYTRUDA and KEYTRUDA QLEX is the adjuvant treatmen=
t of adult patients with renal cell carcinoma (&zwj;RCC&zwj;) at intermedia=
te-high or high risk of recurrence following nephrectomy, or following neph=
rectomy and resection of metastatic lesions.
  </p>
    </td>
    </tr>

    </tbody>
    </table>
    </th>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; bac=
kground-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
bgcolor=3D"#F1F1F1" style=3D"word-break: break-word; mso-hyphenate: none; m=
so-table-lspace: 0pt; mso-table-rspace: 0pt; background-color: #F1F1F1;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"t=
op" style=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 20px 20px=
; word-break: break-word; font-weight: normal;" width=3D"620">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"t=
op" style=3D"mso-hyphenate: none; padding: 20px 20px 20px 20px; word-break:=
 break-word; font-weight: normal; background-color: #ffffff; border: 1px so=
lid #808285;" bgcolor=3D"#ffffff">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"t=
op" style=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-=
size-adjust: none; padding: 0px 0px 0px 0px; word-break: break-word; font-w=
eight: normal;">
    <!-- Accordion Section starts -->
    <div style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text=
-size-adjust: none; -ms-text-size-adjust: none; background-color: white;">
    <!--[if mso | IE]>
    <table align=3D"center" border=3D"0" cellpadding=3D"0" cellspacing=3D"0=
" class=3D"" style=3D"width:570px;" width=3D"570">
    <tr>
    <td style=3D"line-height:0px;font-size:0px;mso-line-height-rule:exactly=
;">
    <![endif]-->
    <div style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text=
-size-adjust: none; -ms-text-size-adjust: none; background: #ffffff; backgr=
ound-color: #ffffff; margin: 0px auto;">
    <table align=3D"center" border=3D"0" cellpadding=3D"0" cellspacing=3D"0=
" role=3D"presentation" style=3D"word-break: break-word; mso-hyphenate: non=
e; mso-table-lspace: 0pt; mso-table-rspace: 0pt; background: #ffffff; backg=
round-color: #ffffff; width: 100%;" width=3D"100%" bgcolor=3D"#ffffff">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"mobile_padding" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; directi=
on: ltr; font-size: 0px; padding: 0px 0px 0px 0px; text-align: center;" ali=
gn=3D"center">
<!--[if mso | IE]>
<table role=3D"presentation" border=3D"0" cellpadding=3D"0" cellspacing=3D"=
0">
<tr>
<td class=3D"" style=3D"vertical-align:top;width:570px;">
<![endif]-->
<div class=3D"mj-column-per-100 mj-outlook-group-fix" style=3D"word-break: =
break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-s=
ize-adjust: none; font-size: 0px; text-align: left; direction: ltr; display=
: inline-block; vertical-align: top; width: 100%;">
<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" role=3D"presentatio=
n" style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: =
0pt; mso-table-rspace: 0pt; vertical-align: top;" width=3D"100%" valign=3D"=
top">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td style=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-=
size-adjust: none; font-size: 0px; padding: 0px; word-break: break-word;">
<table cellspacing=3D"0" cellpadding=3D"0" class=3D"mj-accordion" style=3D"=
word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; mso-tab=
le-rspace: 0pt; width: 100%; border-collapse: collapse; border: none; borde=
r-bottom: none; font-family: Ubuntu, Helvetica, Arial, sans-serif;" width=
=3D"100%">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size=
-adjust: none; -ms-text-size-adjust: none; padding: 0px;">
    <!--[if !mso | IE]><!-->

    <!--<![endif]-->
    <div style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text=
-size-adjust: none; -ms-text-size-adjust: none;">
    <div class=3D"mj-accordion-title" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
;">
    <table cellspacing=3D"0" cellpadding=3D"0" style=3D"word-break: break-w=
ord; mso-hyphenate: none; mso-table-lspace: 0pt; mso-table-rspace: 0pt; wid=
th: 100%; border-bottom: none;" width=3D"100%">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"m=
iddle" style=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; padding: 0px 0px 20px 0px; word-break: break-word; fo=
nt-weight: normal; mso-padding-bottom-alt: 18px;">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 22px; line-height: 24px; text-align: left; color: =
#7C02BB; margin: 0;">
    <strong style=3D"word-break: break-word; mso-hyphenate: none; font-fami=
ly: Arial,  Helvetica,  sans-serif; color: #7C02BB;">Selected Safety Inform=
ation</strong>
    </p>
    </td>
    <!--[if !mso | IE]><!-->
<td class=3D"mj-accordion-ico" style=3D"word-break: break-word; mso-hyphena=
te: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; paddi=
ng: 0px 0px 20px 0px; vertical-align: middle;" width=3D"32" valign=3D"middl=
e">
 =20
    <span class=3D"mj-accordion-more" style=3D"word-break: break-word; mso-=
hyphenate: none; display: none; width: 32px; height: 32px; font-size: 3px; =
line-height: 25px; font-family: Arial, Helvetica, sans-serif; color: #231F2=
0;">
      <img class=3D"desktop_img" src=3D"https://www.us-hh.com/Email/Keytrud=
a/US-PDS-00024/plus_icon-new.png" title=3D"Plus Icon" alt=3D"Plus Icon" wid=
th=3D"32" height=3D"32" style=3D"word-break: break-word; mso-hyphenate: non=
e; border: 0; display: block; max-width: 100%; font-size: 5px; line-height:=
 5px; color: #58595B; display: block; max-width: 100%; cursor: pointer;">
    </span>
    <span class=3D"mj-accordion-less" style=3D"word-break: break-word; mso-=
hyphenate: none; display: none; width: 32px; height: 32px; font-size: 3px; =
line-height: 25px; font-family: Arial, Helvetica, sans-serif; color: #231F2=
0;">
      <img class=3D"desktop_img" src=3D"https://www.us-hh.com/Email/Keytrud=
a/US-PDS-00024/minus-icon-new.png" title=3D"Minus Icon" alt=3D"Minus Icon" =
width=3D"32" height=3D"32" style=3D"word-break: break-word; mso-hyphenate: =
none; border: 0; display: block; max-width: 100%; font-size: 5px; line-heig=
ht: 5px; color: #58595B; cursor: pointer;">
    </span>
 =20
</td>
    <!--<![endif]-->
    </tr>
    </tbody>
    </table>
    </div>
    <div class=3D"mj-accordion" style=3D"word-break: break-word; mso-hyphen=
ate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding: 0px 0px 0px 0px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding: 0px 0px 0px 0px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_subhead" align=3D"left" valign=3D"top" s=
tyle=3D"mso-hyphenate: none; padding: 0px 0px 12px 0px; word-break: break-w=
ord; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 16px; text-align: left; color: #58595B; margin: 0;">
<strong style=3D"word-break: break-word; mso-hyphenate: none; font-family: =
Arial,  Helvetica,  sans-serif;">Contraindications</strong>
</p>
</th>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_subhead" align=3D"left" valign=3D"top" s=
tyle=3D"mso-hyphenate: none; padding: 0px 0px 12px 0px; word-break: break-w=
ord; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 16px; text-align: left; color: #58595B; margin: 0;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif;">KEYTRUDA QLEX is contraindicated in patients=
 with known hypersensitivity to berahyaluronidase alfa, hyaluronidase or to=
 any of its excipients.</span>
</p>
</th>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_subhead" align=3D"left" valign=3D"top" s=
tyle=3D"mso-hyphenate: none; padding: 0px 0px 12px 0px; word-break: break-w=
ord; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 16px; text-align: left; color: #58595B; margin: 0;">
<strong style=3D"word-break: break-word; mso-hyphenate: none; font-family: =
Arial,  Helvetica,  sans-serif;">Severe and Fatal Immune&#00045;Mediated Ad=
verse Reactions</strong>
</p>
</th>
</tr>
    </table>
    </td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top=
" style=3D"mso-hyphenate: none; padding: 0px 0px 0px 6px; word-break: break=
-word; font-weight: normal;">
    <table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt; border: 0px;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" st=
yle=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjus=
t: none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-fami=
ly: Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-l=
ine-height-alt: 21px; mso-line-height-rule: exactly;">
    &#08226;
    </td>
    <td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; mso-line-height-rule: exactly; font-family: Arial, Helvetica, sans-serif;=
 font-size: 16px; color: #58595B;">
    <span style=3D"word-break: break-word; mso-hyphenate: none; font-family=
: Arial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX are monoclonal antibodies that belong to a class=
 of drugs that bind to either the programmed death receptor-1 (&zwj;PD&zwj;=
-&zwj;1&zwj;) or the programmed death ligand 1 (&zwj;PD&zwj;-&zwj;L1&zwj;),=
 blocking the PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 pathway, thereby rem=
oving inhibition of the immune response, potentially breaking peripheral to=
lerance and inducing immune-mediated adverse reactions. Immune-mediated adv=
erse reactions, which may be severe or fatal, can occur in any organ system=
 or tissue, can affect more than one body system simultaneously, and can oc=
cur at any time after starting treatment or after discontinuation of treatm=
ent. Important immune-mediated adverse reactions listed here may not includ=
e all possible severe and fatal immune-mediated adverse reactions.         =
                                                                           =
                                                                           =
                   </span> =20
    </td>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    <!--[if !mso]><!-->
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns mj-accordion-expand staticacc interactive" =
style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adj=
ust: none; -ms-text-size-adjust: none; padding: 0px 0px 0px 0px; display: n=
one;">
   =20
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns mj-accordion-expand" style=3D"word-break: b=
reak-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-si=
ze-adjust: none; padding: 0px 0px 0px 0px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_subhead" align=3D"left" valign=3D"to=
p" style=3D"mso-hyphenate: none; padding: 20px 30px 0px 0px; word-break: br=
eak-word; font-weight: normal;">
    <!--[if mso]>
    <p style=3D"font-family: Arial, Helvetica, sans-serif;font-size: 1px; l=
ine-height:1px; text-align:left;color: #006EAD;margin:0;">
    <strong style=3D"font-family: Arial,  Helvetica,  sans-serif;"></strong=
>
    </p>
    <![endif]-->
    <!--[if !mso] -->
      <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text=
-size-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helveti=
ca, sans-serif; font-size: 16px; line-height: 20px; text-align: left; color=
: #006EAD; margin: 0;">
      <strong style=3D"word-break: break-word; mso-hyphenate: none; font-fa=
mily: Arial,  Helvetica,  sans-serif;">Expand to See Selected Safety Inform=
ation</strong>
      </p>
      <!--[endif]-->
      </th>
      </tr>
      </table>
      </td>
      </tr>
      </table>
     =20
      </td>
      </tr>
      <!--<![endif]-->
      </tbody>
      </table>
      </td>
      </table>
      </div>
      <div class=3D"mj-accordion-content" style=3D"word-break: break-word; =
mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: =
none;">
      <table cellspacing=3D"0" cellpadding=3D"0" style=3D"word-break: break=
-word; mso-hyphenate: none; mso-table-lspace: 0pt; mso-table-rspace: 0pt; w=
idth: 100%; border-bottom: none;" width=3D"100%">
      <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
      <tr style=3D"word-break: break-word; mso-hyphenate: none;">
      <td class=3D"fs11" align=3D"justify" valign=3D"top" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; font-size: 16px; line-height: 22px; font-family: Aria=
l, Helvetica, sans-serif; color: #000; padding: 0px 0px 0px 15px; text-alig=
n: justify;">
      </td>
      </tr>
      </tbody>
      </table>
      <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0=
" style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0=
pt; mso-table-rspace: 0pt;">
      <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyp=
henate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; p=
adding: 0px 0px 0px 0px;">
      <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0=
" style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0=
pt; mso-table-rspace: 0pt;">
      <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
      <tr style=3D"word-break: break-word; mso-hyphenate: none;">
      <th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"t=
op" style=3D"mso-hyphenate: none; padding: 20px 0px 0px 6px; word-break: br=
eak-word; font-weight: normal;">
      <table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0=
" style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0=
pt; mso-table-rspace: 0pt; border: 0px;">
      <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
      <tr style=3D"word-break: break-word; mso-hyphenate: none;">
      <td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" =
style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adj=
ust: none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-fa=
mily: Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso=
-line-height-alt: 21px; mso-line-height-rule: exactly;">
      &#08226;
      </td>
      <td align=3D"left" valign=3D"top" style=3D"word-break: break-word; ms=
o-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: no=
ne; mso-line-height-rule: exactly; font-family: Arial, Helvetica, sans-seri=
f; font-size: 16px; color: #58595B; padding-bottom: 20px;">
      <span style=3D"word-break: break-word; mso-hyphenate: none; font-fami=
ly: Arial,  Helvetica,  sans-serif; color: #58595B;">
Monitor patients closely for symptoms and signs that may be clinical manife=
stations of underlying immune-mediated adverse reactions. Early identificat=
ion and management are essential to ensure safe use of anti&zwj;=E2=80=93&z=
wj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 treatments. Evaluate liver enzy=
mes, creatinine, and thyroid function at baseline and periodically during t=
reatment. In cases of suspected immune-mediated adverse reactions, initiate=
 appropriate workup to exclude alternative etiologies, including infection.=
 Institute medical management promptly, including specialty consultation as=
 appropriate.</span>
      </td>
      </tr>
      <tr style=3D"word-break: break-word; mso-hyphenate: none; padding: 0p=
x 0px 0px 0px;">
      <td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" =
style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adj=
ust: none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-fa=
mily: Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso=
-line-height-alt: 21px; mso-line-height-rule: exactly;">
      &#08226;
      </td>
      <td align=3D"left" valign=3D"top" style=3D"word-break: break-word; ms=
o-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: no=
ne; mso-line-height-rule: exactly; font-family: Arial, Helvetica, sans-seri=
f; font-size: 16px; color: #58595B;">
      <span style=3D"word-break: break-word; mso-hyphenate: none; font-fami=
ly: Arial,  Helvetica,  sans-serif; color: #58595B;">
    Withhold or permanently discontinue KEYTRUDA and KEYTRUDA QLEX dependin=
g on severity of the immune-mediated adverse reaction. In general, if KEYTR=
UDA and KEYTRUDA QLEX require interruption or discontinuation, administer s=
ystemic corticosteroid therapy (&zwj;1 to 2&nbsp;mg&zwj;/&zwj;kg&zwj;/&zwj;=
day prednisone or equivalent&zwj;) until improvement to Grade&nbsp;1 or les=
s. Upon improvement to Grade&nbsp;1 or less, initiate corticosteroid taper =
and continue to taper over at least 1&nbsp;month. Consider administration o=
f other systemic immunosuppressants in patients whose adverse reactions are=
 not controlled with corticosteroid therapy.
    </span>
      </td>
      </tr>
      </tbody>
      </table>
      </th>
      </tr>
      <!--[if !mso]><!-->
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding: 0px 0px 0px 0px;">
   =20
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns staticacc interactive" style=3D"word-break:=
 break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-=
size-adjust: none; padding: 0px 0px 0px 0px; display: none;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_subhead" align=3D"left" valign=3D"to=
p" style=3D"mso-hyphenate: none; padding: 20px 20px 0px 0px; word-break: br=
eak-word; font-weight: normal;">
    <!--[if mso]>
    <p style=3D"font-family: Arial, Helvetica, sans-serif;font-size: 16px; =
line-height:20px; text-align:left;color: #006EAD;margin:0;">
    <strong style=3D"font-family: Arial,  Helvetica,  sans-serif;">Collapse=
</strong>
    </p>
    <![endif]-->
    <!--[if !mso] -->
      <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text=
-size-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helveti=
ca, sans-serif; font-size: 16px; line-height: 20px; text-align: left; color=
: #006EAD; margin: 0;">
      <strong style=3D"word-break: break-word; mso-hyphenate: none; font-fa=
mily: Arial,  Helvetica,  sans-serif;">Collapse</strong>
      </p>
      <!--[endif]-->
      </th>
      </tr>
      </table>
      </td>
      </tr>
      </table>
     =20
      </td>
      </tr>
      <!--<![endif]-->
      </tbody>
      </table>
      </td>
      </table>
      </div>
      </div>
      </td>
      </tr>
      </tbody>
      </table>
      </td>
      </tr>
      </tbody>
      </table>
      </div>
      <!--[if mso | IE]>
    </td>
    </tr>
    </table>
    <![endif]-->
    </td>
    </tr>
    </tbody>
    </table>
    </div>
    <!--[if mso | IE]>
    </td>
    </tr>
    </table>
    <![endif]-->
    </div>
    <!-- Accordion Section ends -->
    </td>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell ssi_headline pd-SSI" align=3D"left" vali=
gn=3D"top" style=3D"mso-hyphenate: none; width: 620px; padding: 0px 26px 0p=
x 26px; word-break: break-word; font-weight: normal; background-color: #F1F=
1F1;" width=3D"620" bgcolor=3D"#F1F1F1">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt; background-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"device_width cell ssi_headline" align=3D"center" valign=3D=
"top" style=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-tex=
t-size-adjust: none; padding: 0px 0px 0px 0px; word-break: break-word; font=
-weight: normal;">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 16px; line-height: 20px; text-align: center; color=
: #006EAD; margin: 0;">
    <strong style=3D"word-break: break-word; mso-hyphenate: none; font-fami=
ly: Arial,  Helvetica,  sans-serif; color: #006EAD; font-style: italic;">Se=
lected
    Safety Information continues below.</strong></p>
    </td>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
     =20
      <tr style=3D"word-break: break-word; mso-hyphenate: none;">
  <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphena=
te: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; backg=
round-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
bgcolor=3D"#F1F1F1" style=3D"word-break: break-word; mso-hyphenate: none; m=
so-table-lspace: 0pt; mso-table-rspace: 0pt; background-color: #F1F1F1;">
      <tr style=3D"word-break: break-word; mso-hyphenate: none;">
        <th class=3D"device_width cell" align=3D"center" valign=3D"top" sty=
le=3D"word-break: break-word; mso-hyphenate: none; width: 620px; padding: 2=
0px; font-weight: normal;" width=3D"620">
          <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=
=3D"0" style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspa=
ce: 0pt; mso-table-rspace: 0pt; background-color: #ffffff;" bgcolor=3D"#fff=
fff">
            <tr style=3D"word-break: break-word; mso-hyphenate: none;">
              <td align=3D"center" style=3D"word-break: break-word; mso-hyp=
henate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; p=
adding: 0; margin: 0;">
                <!--[if mso]>
                <table role=3D"presentation" cellspacing=3D"0" cellpadding=
=3D"0" border=3D"0">
                  <tr>
                    <td>
                      <v:rect xmlns:v=3D"urn:schemas-microsoft-com:vml" fil=
l=3D"true" stroke=3D"false" style=3D"width:620px;height:auto;">
                       =20
                      </v:rect>
                    </td>
                  </tr>
                </table>
                <![endif]-->
                <!--[if !mso]><!-- -->
                <img src=3D"https://img.mailinblue.com/3047716/images/conte=
nt_library/original/68ed0da9828c741c894d3b44.gif" alt=3D"KEYTRUDA QLEX high=
lights: administration times, injection sites, and important dosage info" w=
idth=3D"620" border=3D"0" style=3D"word-break: break-word; mso-hyphenate: n=
one; display: block; width: 100%; max-width: 620px; height: auto; border: 0=
; outline: none; text-decoration: none;">
                <!--<![endif]-->
              </td>
            </tr>
          </table>
        </th>
      </tr>
    </table>
  </td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; backgro=
und-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" bgco=
lor=3D"#F1F1F1" style=3D"word-break: break-word; mso-hyphenate: none; mso-t=
able-lspace: 0pt; mso-table-rspace: 0pt; background-color: #F1F1F1;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"top" =
style=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 20px 20px; wo=
rd-break: break-word; font-weight: normal;" width=3D"620">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_headline pdlr18" align=3D"left" valign=
=3D"top" style=3D"mso-hyphenate: none; padding: 20px 20px 20px 20px; word-b=
reak: break-word; font-weight: normal; background-color: #ffffff; border: 1=
px solid #808285;" bgcolor=3D"#ffffff">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
  <td class=3D"cell display_block mobile__align--left h-auto" align=3D"cent=
er" valign=3D"top" style=3D"word-break: break-word; mso-hyphenate: none; -w=
ebkit-text-size-adjust: none; -ms-text-size-adjust: none; padding: 0px 10px=
 20px 10px; margin: 0 auto; text-align: center;">
    <img class src=3D"https://www.us-hh.com/Email/Keytruda/US-PDS-00024/QSU=
B_HCP_Icon_RGB_Dual_Switch_Expanded.png" title alt=3D"image" width=3D"115" =
border=3D"0" style=3D"word-break: break-word; mso-hyphenate: none; border: =
0; display: block; max-width: 100%; font-size: 5px; line-height: 5px; color=
: #58595B; text-align: center; margin: 0 auto;">

  </td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"center" valign=3D"top" style=3D"ms=
o-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: no=
ne; word-break: break-word; font-weight: normal; font-family: Arial, Helvet=
ica, sans-serif;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 16px; text-align: center; color: #58595B; margin: 0;">
<strong style=3D"word-break: break-word; mso-hyphenate: none; font-family: =
Arial,  Helvetica,  sans-serif; color: #58595B; text-align: center;">
Patients have the option to switch from <span style=3D"word-break: break-wo=
rd; mso-hyphenate: none; color: #449C44;">KEYTRUDA </span>to<span style=3D"=
word-break: break-word; mso-hyphenate: none; color: #449C44;"> KEYTRUDA </s=
pan><span style=3D"word-break: break-word; mso-hyphenate: none; color: #7C0=
2BB;">QLEX</span>&mdash;or <span style=3D"word-break: break-word; mso-hyphe=
nate: none; color: #449C44;">KEYTRUDA</span><span style=3D"word-break: brea=
k-word; mso-hyphenate: none; color: #7C02BB;"> QLEX </span>to<span style=3D=
"word-break: break-word; mso-hyphenate: none; color: #449C44;"> KEYTRUDA</s=
pan>&mdash;at their next scheduled dose</strong></p>
</td>
</tr>

</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>

    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; bac=
kground-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
bgcolor=3D"#F1F1F1" style=3D"word-break: break-word; mso-hyphenate: none; m=
so-table-lspace: 0pt; mso-table-rspace: 0pt; background-color: #F1F1F1;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">

    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"layout columns" valign=3D"top" style=3D"word-break: break-=
word; mso-hyphenate: none; font-weight: normal; padding: 0px 20px 0px 20px;=
">
    <table width=3D"100%" class=3D"mobilebg3" cellspacing=3D"0" cellpadding=
=3D"0" border=3D"0" valign=3D"top" style=3D"word-break: break-word; mso-hyp=
henate: none; mso-table-lspace: 0pt; mso-table-rspace: 0pt; background-imag=
e: url('https://www.us-hh.com/Email/Keytruda/US-PDS-00024/grad-border.jpg')=
; background-position: center center; background-repeat: no-repeat; backgro=
und-size: 100% 100%;" background=3D"https://www.us-hh.com/Email/Keytruda/US=
-PDS-00024/grad-border.jpg">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"column__parent device_width" style=3D"word-break: break-wo=
rd; mso-hyphenate: none; width: 620px; font-weight: normal;" width=3D"620">
<!--[if gte mso 9]>
<v:rect xmlns:v=3D"urn:schemas-microsoft-com:vml" fill=3D"true" stroke=3D"f=
alse" style=3D"width:620px;height:84px;padding:0px 20px 0px 20px; align:cen=
ter;margin:0 auto;">
<v:fill type=3D"frame" src=3D"https://www.us-hh.com/Email/Keytruda/US-PDS-0=
0024/grad-border.jpg" />
<v:textbox inset=3D"0,0,0,0">
<![endif]-->
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
valign=3D"top" style=3D"word-break: break-word; mso-hyphenate: none; mso-ta=
ble-lspace: 0pt; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-=
size-adjust: none; -ms-text-size-adjust: none;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"cell ssi_headline mob-pad45" align=3D"center" valign=3D"to=
p" style=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-s=
ize-adjust: none; word-break: break-word; font-weight: normal; font-family:=
 Arial, Helvetica, sans-serif; padding: 20px 50px 20px 50px;">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 18px; text-align: center; color: #58595B; margin: =
0;">
    <strong style=3D"word-break: break-word; mso-hyphenate: none; font-fami=
ly: Arial,  Helvetica,  sans-serif; color: #58595B; text-align: center;">
For certain patients, treatment with <span style=3D"word-break: break-word;=
 mso-hyphenate: none; color: #449C44;">KEYTRUDA </span><span style=3D"word-=
break: break-word; mso-hyphenate: none; color: #7C02BB;">QLEX</span> offers=
 flexibility by not requiring an infusion chair
</strong></p>
    </td>
    </tr>

    </table>
    </td>
    </tr>
    </table>
    <!--[if gte mso 9]>
    </v:textbox>
    </v:rect>
    <![endif]-->
    </th>
    </tr>
    </table>
    </th>
    </tr>




<tr style=3D"word-break: break-word; mso-hyphenate: none;">
  <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphena=
te: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
      <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
        <tr style=3D"word-break: break-word; mso-hyphenate: none;">
          <th class=3D"device_width spacer" height=3D"20" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; font-weight: normal; height: 20px; fon=
t-size: 20px; line-height: 20px; mso-line-height-rule: exactly; mso-line-he=
ight-alt: 20px;">&nbsp; </th>
        </tr>
      </tbody>
    </table>
  </td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell image_mobile mobile_settings image__widt=
h--100 display_block mobile__align--center mobile__valign--middle notNested=
" align=3D"center" valign=3D"middle" height=3D"68" style=3D"word-break: bre=
ak-word; mso-hyphenate: none; font-weight: normal; border: 0px; width: 620p=
x; padding: 0px 20px 0px 20px; background-color: #EFEFEF;" width=3D"620" bg=
color=3D"#EFEFEF">
        <a href=3D"#" target=3D"_blank" style=3D"word-break: break-word; ms=
o-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: no=
ne;"><img class=3D"desktop_img" src=3D"https://www.us-hh.com/Email/Keytruda=
/US-PDS-00024/learn-more-clinical-data-dsk.png" title alt=3D"image" width=
=3D"620" border=3D"0" style=3D"word-break: break-word; mso-hyphenate: none;=
 border: 0; display: block; font-size: 6px; line-height: 6px; max-width: 10=
0%; color: #58595B; width: 620px;"></a>
        <!--[if !mso] --><a href=3D"#" target=3D"_blank" style=3D"word-brea=
k: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-tex=
t-size-adjust: none;"><img class=3D"mobile_img" src=3D"https://www.us-hh.co=
m/Email/Keytruda/US-PDS-00024/learn-more-clinical-data-mobi.png" title alt=
=3D"image" style=3D"word-break: break-word; mso-hyphenate: none; border: 0;=
 font-size: 6px; line-height: 6px; max-width: 100%; display: none; color: #=
58595B;" width=3D"100%" border=3D"0"></a>
        <!--[endif]-->
    </th>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
  <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphena=
te: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
      <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
        <tr style=3D"word-break: break-word; mso-hyphenate: none;">
          <th class=3D"device_width spacer" height=3D"20" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; font-weight: normal; height: 20px; fon=
t-size: 20px; line-height: 20px; mso-line-height-rule: exactly; mso-line-he=
ight-alt: 20px;">&nbsp; </th>
        </tr>
      </tbody>
    </table>
  </td>
</tr>
    </tbody>
    </table>
    </td>
    </tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; backgro=
und-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" bgco=
lor=3D"#F1F1F1" style=3D"word-break: break-word; mso-hyphenate: none; mso-t=
able-lspace: 0pt; mso-table-rspace: 0pt; background-color: #F1F1F1;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"top" =
style=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 0px 20px; wor=
d-break: break-word; font-weight: normal;" width=3D"620">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"top" =
style=3D"mso-hyphenate: none; padding: 20px 20px 20px 20px; word-break: bre=
ak-word; font-weight: normal; background-color: #ffffff; border: 1px solid =
#808285;" bgcolor=3D"#ffffff">
<!--[if !mso]><!-->


<!--<![endif]-->
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 20px 18px 0px; word-break: break-word; font-weight: normal; =
mso-padding-bottom-alt: 18px;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 22px; line-height: 28px; text-align: left; color: #7C0=
2BB; margin: 0;">
<strong style=3D"word-break: break-word; mso-hyphenate: none; font-family: =
Arial,  Helvetica,  sans-serif; color: #7C02BB;">Selected Safety Informatio=
n <em style=3D"word-break: break-word; mso-hyphenate: none;">(&zwj;continue=
d&zwj;)</em></strong>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->=20
<td class=3D"cell ssi_headline outerSSI" align=3D"left" valign=3D"top" styl=
e=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adj=
ust: none; padding: 0px 20px 7px 0px; word-break: break-word; font-weight: =
normal; display: none;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;">
<strong style=3D"word-break: break-word; mso-hyphenate: none;">Severe and F=
atal Immune&#00045;Mediated Adverse Reactions <em style=3D"word-break: brea=
k-word; mso-hyphenate: none;">(&zwj;continued&zwj;)</em></strong>
</p>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->
<td class=3D"layout columns outerSSI" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 15px 0px; display: none;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Monitor patients closely for symptoms and signs that may be clinical manife=
stations of underlying immune-mediated adverse reactions. Early identificat=
ion and management are essential to ensure safe use of anti&zwj;=E2=80=93&z=
wj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 treatments. Evaluate liver enzy=
mes, creatinine, and thyroid function at baseline and periodically during t=
reatment. In cases of suspected immune-mediated adverse reactions, initiate=
 appropriate workup to exclude alternative etiologies, including infection.=
 Institute medical management promptly, including specialty consultation as=
 appropriate.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->
<td class=3D"layout columns outerSSI" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; display: none;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Withhold or permanently discontinue KEYTRUDA and KEYTRUDA QLEX depending on=
 severity of the immune-mediated adverse reaction. In general, if KEYTRUDA =
and KEYTRUDA QLEX require interruption or discontinuation, administer syste=
mic corticosteroid therapy (&zwj;1 to 2&nbsp;mg&zwj;/&zwj;kg&zwj;/&zwj;day =
prednisone or equivalent&zwj;) until improvement to Grade&nbsp;1 or less. U=
pon improvement to Grade&nbsp;1 or less, initiate corticosteroid taper and =
continue to taper over at least 1&nbsp;month. Consider administration of ot=
her systemic immunosuppressants in patients whose adverse reactions are not=
 controlled with corticosteroid therapy.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->
<td class=3D"cell ssi_headline outerSSI" align=3D"left" valign=3D"top" styl=
e=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adj=
ust: none; padding: 0px 0px 7px 0px; word-break: break-word; font-weight: n=
ormal; display: none;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Immune-Mediated Pneumonitis
</p>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
  <!--[if !mso] -->
<td class=3D"layout columns outerSSI" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; display: none;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated pneumonitis. The incid=
ence is higher in patients who have received prior thoracic radiation. Immu=
ne-mediated pneumonitis occurred in 3.4% (&zwj;94/2799&zwj;) of patients re=
ceiving KEYTRUDA, including fatal (&zwj;0.1%&zwj;), Grade&nbsp;4 (&zwj;0.3%=
&zwj;), Grade&nbsp;3 (&zwj;0.9%&zwj;), and Grade&nbsp;2 (&zwj;1.3%&zwj;) re=
actions. Systemic corticosteroids were required in 67% (&zwj;63/94&zwj;) of=
 patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3%=
 (&zwj;36&zwj;) and withholding in 0.9% (&zwj;26&zwj;) of patients. All pat=
ients who were withheld reinitiated KEYTRUDA after symptom improvement; of =
these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients. =
Immune-mediated pneumonitis occurred in 5% (&zwj;13/251&zwj;) of patients r=
eceiving KEYTRUDA QLEX in combination with chemotherapy, including fatal (&=
zwj;0.4%&zwj;), Grade&nbsp;3 (&zwj;2%&zwj;), and Grade&nbsp;2 (&zwj;1.2%&zw=
j;) adverse reactions.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->=20
<td class=3D"cell ssi_headline outerSSI" align=3D"left" valign=3D"top" styl=
e=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adj=
ust: none; padding: 0px 20px 7px 0px; word-break: break-word; font-weight: =
normal; display: block;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;">
<strong style=3D"word-break: break-word; mso-hyphenate: none;">Severe and F=
atal Immune&#00045;Mediated Adverse Reactions <em style=3D"word-break: brea=
k-word; mso-hyphenate: none;">(&zwj;continued&zwj;)</em></strong>
</p>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->
<td class=3D"layout columns outerSSI" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 15px 0px; display: block;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Monitor patients closely for symptoms and signs that may be clinical manife=
stations of underlying immune-mediated adverse reactions. Early identificat=
ion and management are essential to ensure safe use of anti&zwj;=E2=80=93&z=
wj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 treatments. Evaluate liver enzy=
mes, creatinine, and thyroid function at baseline and periodically during t=
reatment. In cases of suspected immune-mediated adverse reactions, initiate=
 appropriate workup to exclude alternative etiologies, including infection.=
 Institute medical management promptly, including specialty consultation as=
 appropriate.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->
<td class=3D"layout columns outerSSI" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; display: block;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Withhold or permanently discontinue KEYTRUDA and KEYTRUDA QLEX depending on=
 severity of the immune-mediated adverse reaction. In general, if KEYTRUDA =
and KEYTRUDA QLEX require interruption or discontinuation, administer syste=
mic corticosteroid therapy (&zwj;1 to 2&nbsp;mg&zwj;/&zwj;kg&zwj;/&zwj;day =
prednisone or equivalent&zwj;) until improvement to Grade&nbsp;1 or less. U=
pon improvement to Grade&nbsp;1 or less, initiate corticosteroid taper and =
continue to taper over at least 1&nbsp;month. Consider administration of ot=
her systemic immunosuppressants in patients whose adverse reactions are not=
 controlled with corticosteroid therapy.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<!--[if !mso] -->
<td class=3D"cell ssi_headline outerSSI" align=3D"left" valign=3D"top" styl=
e=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adj=
ust: none; padding: 0px 0px 7px 0px; word-break: break-word; font-weight: n=
ormal; display: block;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Immune-Mediated Pneumonitis
</p>
</td>
<!--[endif]-->
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
  <!--[if !mso] -->
<td class=3D"layout columns outerSSI" style=3D"word-break: break-word; mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; display: block;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated pneumonitis. The incid=
ence is higher in patients who have received prior thoracic radiation. Immu=
ne-mediated pneumonitis occurred in 3.4% (&zwj;94/2799&zwj;) of patients re=
ceiving KEYTRUDA, including fatal (&zwj;0.1%&zwj;), Grade&nbsp;4 (&zwj;0.3%=
&zwj;), Grade&nbsp;3 (&zwj;0.9%&zwj;), and Grade&nbsp;2 (&zwj;1.3%&zwj;) re=
actions. Systemic corticosteroids were required in 67% (&zwj;63/94&zwj;) of=
 patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3%=
 (&zwj;36&zwj;) and withholding in 0.9% (&zwj;26&zwj;) of patients. All pat=
ients who were withheld reinitiated KEYTRUDA after symptom improvement; of =
these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients. =
Immune-mediated pneumonitis occurred in 5% (&zwj;13/251&zwj;) of patients r=
eceiving KEYTRUDA QLEX in combination with chemotherapy, including fatal (&=
zwj;0.4%&zwj;), Grade&nbsp;3 (&zwj;2%&zwj;), and Grade&nbsp;2 (&zwj;1.2%&zw=
j;) adverse reactions.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>



<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 7px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Immune-Mediated Colitis
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated colitis, which may pre=
sent with diarrhea. Cytomegalovirus infection/reactivation has been reporte=
d in patients with corticosteroid-refractory immune-mediated colitis. In ca=
ses of corticosteroid-refractory colitis, consider repeating infectious wor=
kup to exclude alternative etiologies.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Immune-mediated colitis occurred in 1.7% (&zwj;48/2799&zwj;) of patients re=
ceiving KEYTRUDA, including Grade&nbsp;4 (&zwj;&lt;&zwj;0.1%&zwj;), Grade&n=
bsp;3 (&zwj;1.1%&zwj;), and Grade&nbsp;2 (&zwj;0.4%&zwj;) reactions. System=
ic corticosteroids were required in 69% (&zwj;33/48&zwj;); additional immun=
osuppressant therapy was required in 4.2% of patients. Colitis led to perma=
nent discontinuation of KEYTRUDA in 0.5% (&zwj;15&zwj;) and withholding in =
0.5% (&zwj;13&zwj;) of patients. All patients who were withheld reinitiated=
 KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis =
resolved in 85% of the 48 patients. Immune-mediated colitis occurred in 1.2=
% (&zwj;3/251&zwj;) of patients receiving KEYTRUDA QLEX in combination with=
 chemotherapy, including Grade&nbsp;3 (&zwj;0.8%&zwj;) and Grade&nbsp;2 (&z=
wj;0.4%&zwj;) adverse reactions.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 5px 7px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Hepatotoxicity and Immune-Mediated Hepatitis
</p>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">   =20
KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated hepatitis. Immune-medi=
ated hepatitis occurred in 0.7% (&zwj;19/2799&zwj;) of patients receiving K=
EYTRUDA, including Grade&nbsp;4 (&zwj;&lt;&zwj;0.1%&zwj;), Grade&nbsp;3 (&z=
wj;0.4%&zwj;), and Grade&nbsp;2 (&zwj;0.1%&zwj;) reactions. Systemic cortic=
osteroids were required in 68% (&zwj;13/19&zwj;) of patients; additional im=
munosuppressant therapy was required in 11% of patients. Hepatitis led to p=
ermanent discontinuation of KEYTRUDA in 0.2% (&zwj;6&zwj;) and withholding =
in 0.3% (&zwj;9&zwj;) of patients. All patients who were withheld reinitiat=
ed KEYTRUDA after symptom improvement; of these, none had recurrence. Hepat=
itis resolved in 79% of the 19 patients. Immune-mediated hepatitis occurred=
 in 0.4% (&zwj;1/251&zwj;) of patients receiving KEYTRUDA QLEX in combinati=
on with chemotherapy, including Grade&nbsp;2 (&zwj;0.4%&zwj;) adverse react=
ions.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 7px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Immune-Mediated Endocrinopathies
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><em style=3D"word-break: break-word; mso-hyphenate: none;"=
>Adrenal Insufficiency</em>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause primary or secondary adrenal insuffici=
ency. For Grade&nbsp;2 or higher, initiate symptomatic treatment, including=
 hormone replacement as clinically indicated. Withhold KEYTRUDA and KEYTRUD=
A QLEX depending on severity. Adrenal insufficiency occurred in 0.8% (&zwj;=
22/2799&zwj;) of patients receiving KEYTRUDA, including Grade&nbsp;4 (&zwj;=
&lt;&zwj;0.1%&zwj;), Grade&nbsp;3 (&zwj;0.3%&zwj;), and Grade&nbsp;2 (&zwj;=
0.3%&zwj;) reactions. Systemic corticosteroids were required in 77% (&zwj;1=
7/22&zwj;) of patients; of these, the majority remained on systemic cortico=
steroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUD=
A in &lt;&zwj;0.1% (&zwj;1&zwj;) and withholding in 0.3% (&zwj;8&zwj;) of p=
atients. All patients who were withheld reinitiated KEYTRUDA after symptom =
improvement. Adrenal insufficiency occurred in 2% (&zwj;5/251&zwj;) of pati=
ents receiving KEYTRUDA QLEX in combination with chemotherapy, including Gr=
ade&nbsp;3 (&zwj;0.4%&zwj;) and Grade&nbsp;2 (&zwj;0.8%&zwj;) adverse react=
ions.   =20
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><em style=3D"word-break: break-word; mso-hyphenate: none;"=
>Hypophysitis</em>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated hypophysitis. Hypophys=
itis can present with acute symptoms associated with mass effect such as he=
adache, photophobia, or visual field defects. Hypophysitis can cause hypopi=
tuitarism. Initiate hormone replacement as indicated. Withhold or permanent=
ly discontinue KEYTRUDA and KEYTRUDA QLEX depending on severity.=20
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Hypophysitis occurred in 0.6% (&zwj;17/2799&zwj;) of patients receiving KEY=
TRUDA, including Grade&nbsp;4 (&zwj;&lt;&zwj;0.1%&zwj;), Grade&nbsp;3 (&zwj=
;0.3%&zwj;), and Grade&nbsp;2 (&zwj;0.2%&zwj;) reactions. Systemic corticos=
teroids were required in 94% (&zwj;16/17&zwj;) of patients; of these, the m=
ajority remained on systemic corticosteroids. Hypophysitis led to permanent=
 discontinuation of KEYTRUDA in 0.1% (&zwj;4&zwj;) and withholding in 0.3% =
(&zwj;7&zwj;) of patients. All patients who were withheld reinitiated KEYTR=
UDA after symptom improvement.=20
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>


<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><em style=3D"word-break: break-word; mso-hyphenate: none;"=
>Thyroid Disorders</em>
</p>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated thyroid disorders. Thy=
roiditis can present with or without endocrinopathy. Hypothyroidism can fol=
low hyperthyroidism. Initiate hormone replacement for hypothyroidism or ins=
titute medical management of hyperthyroidism as clinically indicated. Withh=
old or permanently discontinue KEYTRUDA and KEYTRUDA QLEX depending on seve=
rity.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">

Thyroiditis occurred in 0.6% (&zwj;16/2799&zwj;) of patients receiving KEYT=
RUDA, including Grade&nbsp;2 (&zwj;0.3%&zwj;). None discontinued, but KEYTR=
UDA was withheld in &lt;&zwj;0.1% (&zwj;1&zwj;) of patients.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">

Hyperthyroidism occurred in 3.4% (&zwj;96/2799&zwj;) of patients receiving =
KEYTRUDA, including Grade&nbsp;3 (&zwj;0.1%&zwj;) and Grade&nbsp;2 (&zwj;0.=
8%&zwj;). It led to permanent discontinuation of KEYTRUDA in &lt;&zwj;0.1% =
(&zwj;2&zwj;) and withholding in 0.3% (&zwj;7&zwj;) of patients. All patien=
ts who were withheld reinitiated KEYTRUDA after symptom improvement. Hypoth=
yroidism occurred in 8% (&zwj;237/2799&zwj;) of patients receiving KEYTRUDA=
, including Grade&nbsp;3 (&zwj;0.1%&zwj;) and Grade&nbsp;2 (&zwj;6.2%&zwj;)=
. It led to permanent discontinuation of KEYTRUDA in &lt;&zwj;0.1% (&zwj;1&=
zwj;) and withholding in 0.5% (&zwj;14&zwj;) of patients. All patients who =
were withheld reinitiated KEYTRUDA after symptom improvement. The majority =
of patients with hypothyroidism required long-term thyroid hormone replacem=
ent.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Thyroiditis occurred in 0.4% (&zwj;1/251&zwj;) of patients receiving KEYTRU=
DA QLEX in combination with chemotherapy, including Grade&nbsp;2 (&zwj;0.4%=
&zwj;). Hyperthyroidism occurred in 8% (&zwj;20/251&zwj;) of patients recei=
ving KEYTRUDA QLEX in combination with chemotherapy, including Grade&nbsp;2=
 (&zwj;3.2%&zwj;). Hypothyroidism occurred in 14% (&zwj;35/251&zwj;) of pat=
ients receiving KEYTRUDA QLEX in combination with chemotherapy, including G=
rade&nbsp;2 (&zwj;11%&zwj;).
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><em style=3D"word-break: break-word; mso-hyphenate: none;"=
>Type 1 Diabetes Mellitus (&zwj;DM&zwj;), Which Can Present With Diabetic K=
etoacidosis</em>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">

Monitor patients for hyperglycemia or other signs and symptoms of diabetes.=
 Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA=
 and KEYTRUDA QLEX depending on severity. Type 1 DM occurred in 0.2% (&zwj;=
6/2799&zwj;) of patients receiving KEYTRUDA. It led to permanent discontinu=
ation in &lt;&zwj;0.1% (&zwj;1&zwj;) and withholding of KEYTRUDA in &lt;&zw=
j;0.1% (&zwj;1&zwj;) of patients. All patients who were withheld reinitiate=
d KEYTRUDA after symptom improvement. Type 1 diabetes mellitus occurred in =
0.4% (&zwj;1/251&zwj;) of patients receiving KEYTRUDA QLEX in combination w=
ith chemotherapy.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Immune-Mediated Nephritis With Renal Dysfunction
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated nephritis.  =20
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Immune-mediated nephritis occurred in 0.3% (&zwj;9/2799&zwj;) of patients r=
eceiving KEYTRUDA, including Grade&nbsp;4 (&zwj;&lt;&zwj;0.1%&zwj;), Grade&=
nbsp;3 (&zwj;0.1%&zwj;), and Grade&nbsp;2 (&zwj;0.1%&zwj;) reactions. Syste=
mic corticosteroids were required in 89% (&zwj;8/9&zwj;) of patients. Nephr=
itis led to permanent discontinuation of KEYTRUDA in 0.1% (&zwj;3&zwj;) and=
 withholding in 0.1% (&zwj;3&zwj;) of patients. All patients who were withh=
eld reinitiated KEYTRUDA after symptom improvement; of these, none had recu=
rrence. Nephritis resolved in 56% of the 9 patients.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>


<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Immune-Mediated Dermatologic Adverse Reactions
</p>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">

KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated rash or dermatitis. Ex=
foliative dermatitis, including Stevens-Johnson syndrome, drug rash with eo=
sinophilia and systemic symptoms, and toxic epidermal necrolysis, has occur=
red with anti&zwj;=E2=80=93&zwj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 tr=
eatments. Topical emollients and/or topical corticosteroids may be adequate=
 to treat mild to moderate nonexfoliative rashes. Withhold or permanently d=
iscontinue KEYTRUDA and KEYTRUDA QLEX depending on severity.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">

Immune-mediated dermatologic adverse reactions occurred in 1.4% (&zwj;38/27=
99&zwj;) of patients receiving KEYTRUDA, including Grade&nbsp;3 (&zwj;1%&zw=
j;) and Grade&nbsp;2 (&zwj;0.1%&zwj;) reactions. Systemic corticosteroids w=
ere required in 40% (&zwj;15/38&zwj;) of patients. These reactions led to p=
ermanent discontinuation in 0.1% (&zwj;2&zwj;) and withholding of KEYTRUDA =
in 0.6% (&zwj;16&zwj;) of patients. All patients who were withheld reinitia=
ted KEYTRUDA after symptom improvement; of these, 6% had recurrence. The re=
actions resolved in 79% of the 38 patients. Immune-mediated dermatologic ad=
verse reactions occurred in 1.6% (&zwj;4/251&zwj;) of patients receiving KE=
YTRUDA QLEX in combination with chemotherapy, including Grade&nbsp;4 (&zwj;=
0.8%&zwj;) and Grade&nbsp;3 (&zwj;0.8%&zwj;) adverse reactions.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; text-decoration: underline; margin: 0;">
Other Immune-Mediated Adverse Reactions
</p>
</td>
</tr>

<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">

The following clinically significant immune-mediated adverse reactions occu=
rred at an incidence of &lt;&zwj;1% (&zwj;unless otherwise noted&zwj;) in p=
atients who received KEYTRUDA, KEYTRUDA QLEX, or were reported with the use=
 of other anti&zwj;=E2=80=93&zwj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 t=
reatments. Severe or fatal cases have been reported for some of these adver=
se reactions. <em style=3D"word-break: break-word; mso-hyphenate: none;">Ca=
rdiac/Vascular:</em> Myocarditis, pericarditis, vasculitis; <em style=3D"wo=
rd-break: break-word; mso-hyphenate: none;">Nervous System:</em> Meningitis=
, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia =
gravis (&zwj;including exacerbation&zwj;), Guillain-Barr=C3=A9 syndrome, ne=
rve paresis, autoimmune neuropathy; <em style=3D"word-break: break-word; ms=
o-hyphenate: none;">Ocular:</em> Uveitis, iritis and other ocular inflammat=
ory toxicities can occur. Some cases can be associated with retinal detachm=
ent. Various grades of visual impairment, including blindness, can occur. I=
f uveitis occurs in combination with other immune-mediated adverse reaction=
s, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treat=
ment with systemic steroids to reduce the risk of permanent vision loss; <e=
m style=3D"word-break: break-word; mso-hyphenate: none;">Gastrointestinal:<=
/em> Pancreatitis, to include increases in serum amylase and lipase levels,=
 gastritis (&zwj;2.8%&zwj;), duodenitis; <em style=3D"word-break: break-wor=
d; mso-hyphenate: none;">Musculoskeletal and Connective Tissue:</em> Myosit=
is/polymyositis, rhabdomyolysis (&zwj;and associated sequelae, including re=
nal failure&zwj;), arthritis (&zwj;1.5%&zwj;), polymyalgia rheumatica; <em =
style=3D"word-break: break-word; mso-hyphenate: none;">Endocrine:</em> Hypo=
parathyroidism; <em style=3D"word-break: break-word; mso-hyphenate: none;">=
Hematologic/Immune:</em> Hemolytic anemia, aplastic anemia, hemophagocytic =
lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic n=
ecrotizing lymphadenitis (&zwj;Kikuchi lymphadenitis&zwj;), sarcoidosis, im=
mune thrombocytopenic purpura, solid organ transplant rejection, other tran=
splant (&zwj;including corneal graft&zwj;) rejection.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><strong style=3D"word-break: break-word; mso-hyphenate: no=
ne;">Hypersensitivity and Infusion- or Administration-Related Reactions</st=
rong>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
KEYTRUDA and KEYTRUDA QLEX can cause severe or life-threatening administrat=
ion-related reactions, including hypersensitivity and anaphylaxis. With KEY=
TRUDA and KEYTRUDA QLEX, monitor for signs and symptoms of infusion- and ad=
ministration-related systemic reactions including rigors, chills, wheezing,=
 pruritus, flushing, rash, hypotension, hypoxemia, and fever. Infusion-rela=
ted reactions have been reported in 0.2% of 2799 patients receiving KEYTRUD=
A. Interrupt or slow the rate of infusion for Grade&nbsp;1 or Grade&nbsp;2 =
reactions. For Grade&nbsp;3 or Grade&nbsp;4 reactions, stop infusion and pe=
rmanently discontinue KEYTRUDA. Hypersensitivity and administration-related=
 systemic reactions occurred in 3.2% (&zwj;8/251&zwj;) of patients receivin=
g KEYTRUDA QLEX in combination with platinum doublet chemotherapy, includin=
g Grade&nbsp;2 (&zwj;2.8%&zwj;). Interrupt injection (&zwj;if not already f=
ully administered&zwj;) and resume if symptoms resolve for mild or moderate=
 systemic reactions. For severe or life-threatening systemic reactions, sto=
p injection and permanently discontinue KEYTRUDA QLEX.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 10px 10px 0px; word-break: break-word; font-weight: normal;"=
>
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><strong style=3D"word-break: break-word; mso-hyphenate: no=
ne;">Complications of Allogeneic Hematopoietic Stem Cell Transplantation (&=
zwj;HSCT&zwj;)</strong>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Fatal and other serious complications can occur in patients who receive all=
ogeneic HSCT before or after anti&zwj;=E2=80=93&zwj;PD&zwj;-&zwj;1&zwj;/&zw=
j;PD&zwj;-&zwj;L1 treatments. Transplant-related complications include hype=
racute graft-versus-host disease (&zwj;GVHD&zwj;), acute and chronic GVHD, =
hepatic veno-occlusive disease after reduced intensity conditioning, and st=
eroid-requiring febrile syndrome (&zwj;without an identified infectious cau=
se&zwj;). These complications may occur despite intervening therapy between=
 anti&zwj;=E2=80=93&zwj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 treatments=
 and allogeneic HSCT. Follow patients closely for evidence of these complic=
ations and intervene promptly. Consider the benefit vs risks of using anti&=
zwj;=E2=80=93&zwj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 treatments prior=
 to or after an allogeneic HSCT.   =20
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><strong style=3D"word-break: break-word; mso-hyphenate: no=
ne;">Increased Mortality in Patients With Multiple Myeloma</strong>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
In trials in patients with multiple myeloma, the addition of KEYTRUDA to a =
thalidomide analogue plus dexamethasone resulted in increased mortality. Tr=
eatment of these patients with an anti&zwj;=E2=80=93&zwj;PD&zwj;-&zwj;1&zwj=
;/&zwj;PD&zwj;-&zwj;L1 treatment in this combination is not recommended out=
side of controlled trials.
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><strong style=3D"word-break: break-word; mso-hyphenate: no=
ne;">
Embryofetal Toxicity</strong>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Based on their mechanism of action, KEYTRUDA and KEYTRUDA QLEX can each cau=
se fetal harm when administered to a pregnant woman. Advise women of this p=
otential risk. In females of reproductive potential, verify pregnancy statu=
s prior to initiating KEYTRUDA or KEYTRUDA QLEX and advise them to use effe=
ctive contraception during treatment and for 4&nbsp;months after the last d=
ose.   =20
</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><strong style=3D"word-break: break-word; mso-hyphenate: no=
ne;">Adverse Reactions</strong>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
In study MK-347A-D77, when KEYTRUDA QLEX was administered with chemotherapy=
 in metastatic non&zwj;=E2=80=93&zwj;small cell lung cancer (&zwj;NSCLC&zwj=
;), serious adverse reactions occurred in 39% of patients. Serious adverse =
reactions in &ge;&zwj;1% of patients who received KEYTRUDA QLEX were pneumo=
nia (&zwj;10%&zwj;), thrombocytopenia (&zwj;4%&zwj;), febrile neutropenia (=
&zwj;4%&zwj;), neutropenia (&zwj;2.8%&zwj;), musculoskeletal pain (&zwj;2%&=
zwj;), pneumonitis (&zwj;2%&zwj;), diarrhea (&zwj;1.6%&zwj;), rash (&zwj;1.=
2%&zwj;), respiratory failure (&zwj;1.2%&zwj;), and anemia (&zwj;1.2%&zwj;)=
. Fatal adverse reactions occurred in 10% of patients including pneumonia (=
&zwj;3.2%&zwj;), neutropenic sepsis (&zwj;2%&zwj;), death not otherwise spe=
cified (&zwj;1.6%&zwj;), respiratory failure (&zwj;1.2%&zwj;), parotitis (&=
zwj;0.4%&zwj;), pneumonitis (&zwj;0.4%&zwj;), pneumothorax (&zwj;0.4%&zwj;)=
, pulmonary embolism (&zwj;0.4%&zwj;), neutropenic colitis (&zwj;0.4%&zwj;)=
, and seizure (&zwj;0.4%&zwj;). KEYTRUDA QLEX was permanently discontinued =
due to an adverse reaction in 16% of 251 patients. Adverse reactions which =
resulted in permanent discontinuation of KEYTRUDA QLEX in &ge;&zwj;2% of pa=
tients included pneumonia and pneumonitis. Dosage interruptions of KEYTRUDA=
 QLEX due to an adverse reaction occurred in 45% of patients. Adverse react=
ions which required dosage interruption in &ge;&zwj;2% of patients included=
 neutropenia, anemia, thrombocytopenia, pneumonia, rash, and increased aspa=
rtate aminotransferase. The most common adverse reactions (&zwj;&ge;&zwj;20=
%&zwj;) were nausea (&zwj;25%&zwj;), fatigue (&zwj;25%&zwj;), and musculosk=
eletal pain (&zwj;21%&zwj;).</span></td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>


<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 10px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the ad=
juvant treatment of renal cell carcinoma, serious adverse reactions occurre=
d in 20% of patients receiving KEYTRUDA; the serious adverse reactions (&zw=
j;&ge;&zwj;1%&zwj;) were acute kidney injury, adrenal insufficiency, pneumo=
nia, colitis, and diabetic ketoacidosis (&zwj;1% each&zwj;). Fatal adverse =
reactions occurred in 0.2% including 1 case of pneumonia. Discontinuation o=
f KEYTRUDA due to adverse reactions occurred in 21% of 488 patients; the mo=
st common (&zwj;&ge;&zwj;1%&zwj;) were increased alanine aminotransferase (=
&zwj;ALT&zwj;) (&zwj;1.6%&zwj;), colitis (&zwj;1%&zwj;), and adrenal insuff=
iciency (&zwj;1%&zwj;). The most common adverse reactions (&zwj;&ge;&zwj;20=
%&zwj;) were musculoskeletal pain (&zwj;41%&zwj;), fatigue (&zwj;40%&zwj;),=
 rash (&zwj;30%&zwj;), diarrhea (&zwj;27%&zwj;), pruritus (&zwj;23%&zwj;), =
and hypothyroidism (&zwj;21%&zwj;).</span></td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>


<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"cell ssi_headline" align=3D"left" valign=3D"top" style=3D"mso-=
hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none=
; padding: 0px 0px 10px 0px; word-break: break-word; font-weight: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 18px; text-align: left; color: #585=
95B; margin: 0;"><strong style=3D"word-break: break-word; mso-hyphenate: no=
ne;">
Lactation</strong>
</p>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 15px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<th class=3D"device_width cell ssi_bullet" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 6px; word-br=
eak: break-word; font-weight: normal;" width=3D"600">
<table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt; border: 0px;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"list_item_0" align=3D"left" valign=3D"top" width=3D"17" style=
=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: =
none; -ms-text-size-adjust: none; width: 17px; color: #58595B; font-family:=
 Arial, Helvetica, sans-serif; font-size: 19px; line-height: 19px; mso-line=
-height-alt: 19px;">
&#08226;</td>
<td align=3D"left" valign=3D"top" style=3D"word-break: break-word; mso-hyph=
enate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; ms=
o-line-height-rule: exactly; line-height: 18px; font-family: Arial, Helveti=
ca, sans-serif; font-size: 14px; color: #58595B;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B;">
Because of the
potential for
serious adverse
reactions in
breastfed
children, advise
women not to
breastfeed
during treatment
and for 4&nbsp;months
after the last
dose.</span></td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"device_width cell ssi_headline" align=3D"left" valign=3D"top" =
style=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size=
-adjust: none; padding: 0px 0px 0px 0px; word-break: break-word; font-weigh=
t: normal;">
<p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-=
adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica, sa=
ns-serif; font-size: 14px; line-height: 20px; text-align: left; color: #007=
6AD; margin: 0;">
<span style=3D"word-break: break-word; mso-hyphenate: none; font-family: Ar=
ial,  Helvetica,  sans-serif; color: #58595B; font-weight: 700;">
Before prescribing KEYTRUDA or KEYTRUDA QLEX, please read the accompanying =
Prescribing Information for <a href=3D"https://www.merck.com/product/usa/pi=
_circulars/k/keytruda/keytruda_pi.pdf?UTM_term=3DBottomPI" target=3D"_blank=
" style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-a=
djust: none; -ms-text-size-adjust: none; color: #0076AD; font-weight: 700;"=
><u style=3D"word-break: break-word; mso-hyphenate: none;">KEYTRUDA</u></a>=
 and <a href=3D"#" target=3D"_blank" style=3D"word-break: break-word; mso-h=
yphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none;=
 color: #0076AD; font-weight: 700;"><u style=3D"word-break: break-word; mso=
-hyphenate: none;">KEYTRUDA QLEX</u></a>. The Medication Guides for <a href=
=3D"https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.p=
df" target=3D"_blank" style=3D"word-break: break-word; mso-hyphenate: none;=
 -webkit-text-size-adjust: none; -ms-text-size-adjust: none; color: #0076AD=
; font-weight: 700;"><u style=3D"word-break: break-word; mso-hyphenate: non=
e;">KEYTRUDA</u></a> and <a href=3D"#" target=3D"_blank" style=3D"word-brea=
k: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-tex=
t-size-adjust: none; color: #0076AD; font-weight: 700;"><u style=3D"word-br=
eak: break-word; mso-hyphenate: none;">KEYTRUDA QLEX</u></a> also are avail=
able.
</span>
</p>
</td>
</tr>
</tbody>
</table>

</th>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 0px 0px; background-color: #F1F1F1;" bgcolor=3D"#F1F1F1">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" bgco=
lor=3D"#F1F1F1" style=3D"word-break: break-word; mso-hyphenate: none; mso-t=
able-lspace: 0pt; mso-table-rspace: 0pt; background-color: #F1F1F1;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;"><tr style=3D"=
word-break: break-word; mso-hyphenate: none;"><th class=3D"device_width spa=
cer" height=3D"20" style=3D"word-break: break-word; mso-hyphenate: none; fo=
nt-weight: normal; height: 20px; font-size: 20px; line-height: 20px; border=
: 0px; padding: 0px; border-bottom: 1px solid #BEBEBE;">&nbsp;</th>
</tr>
</tbody></table>
</td>
</tr>

    </tbody>
    </table>
    <table class=3D"merck_footer device_width" width=3D"660" cellspacing=3D=
"0" cellpadding=3D"0" border=3D"0" align=3D"center" style=3D"word-break: br=
eak-word; mso-hyphenate: none; mso-table-lspace: 0pt; mso-table-rspace: 0pt=
; margin: 0 auto; background-color: #ffffff;" bgcolor=3D"#ffffff">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding: 0px 0px 0px 0px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width spacer" height=3D"40" style=3D"word-break: br=
eak-word; mso-hyphenate: none; font-weight: normal; height: 40px; font-size=
: 40px; line-height: 40px; mso-line-height-rule: exactly; mso-line-height-a=
lt: 35px;">
    &nbsp;
    </th>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding: 0px 10px 0px 10px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell body_copy" align=3D"left" valign=3D"top"=
 style=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 0px; word=
-break: break-word; font-weight: normal;" width=3D"600">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 14px; line-height: 22px; text-align: center; color=
: #58595B; margin: 0;">
    &nbsp;
    <a href=3D"#" target=3D"_blank" style=3D"word-break: break-word; mso-hy=
phenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; =
text-decoration: none;"><strong style=3D"word-break: break-word; mso-hyphen=
ate: none; font-family: Arial,  Helvetica,  sans-serif; color: #006ead;"><u=
 style=3D"word-break: break-word; mso-hyphenate: none;">keytrudahcp.com</u>=
</strong></a>&nbsp;
    </p>
    </th>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class align=3D"left" valign=3D"top" height=3D"12" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; font-size: 12px; line-height: 12px; font-family: Aria=
l, Helvetica, sans-serif; color: #58595B; padding: 0px 0px 0px 0px; backgro=
und-color: #ffffff;" bgcolor=3D"#ffffff">
    &nbsp;</td>
    </tr>
    </tbody>
    </table>
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">

    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell body_copy" align=3D"left" valign=3D"top"=
 style=3D"mso-hyphenate: none; width: 540px; padding: 0px 30px 0px 30px; wo=
rd-break: break-word; font-weight: normal;" width=3D"540">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 14px; line-height: 22px; text-align: center; color=
: #58595B; margin: 0;">
    &nbsp;
    <a href=3D"#" target=3D"_blank" style=3D"word-break: break-word; mso-hy=
phenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; =
text-decoration: none;"><strong style=3D"word-break: break-word; mso-hyphen=
ate: none; font-family: Arial,  Helvetica,  sans-serif; color: #006ead;"><u=
 style=3D"word-break: break-word; mso-hyphenate: none;">Ask
    Merck</u></strong></a>&nbsp;
    </p>
    </th>
    </tr>

    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class align=3D"left" valign=3D"top" height=3D"12" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; font-size: 12px; line-height: 12px; font-family: Aria=
l, Helvetica, sans-serif; color: #58595B; padding: 0px 0px 0px 0px; backgro=
und-color: #ffffff;" bgcolor=3D"#ffffff">
    &nbsp;</td>
    </tr>
    </tbody>
    </table>
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell body_copy" align=3D"left" valign=3D"top"=
 style=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 0px; word=
-break: break-word; font-weight: normal;" width=3D"600">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 14px; line-height: 22px; text-align: center; color=
: #58595B; margin: 0;">
&nbsp;
    <a href=3D"#" target=3D"_blank" style=3D"word-break: break-word; mso-hy=
phenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; =
text-decoration: none;"><strong style=3D"word-break: break-word; mso-hyphen=
ate: none; font-family: Arial,  Helvetica,  sans-serif; color: #006ead;"><u=
 style=3D"word-break: break-word; mso-hyphenate: none;">Learn
    About<br style=3D"word-break: break-word; mso-hyphenate: none;"> The Me=
rck
    Access Program</u></strong><strong style=3D"word-break: break-word; mso=
-hyphenate: none; font-family: Arial,  Helvetica,  sans-serif; color: #006e=
ad;">
    &#00062;</strong></a>&nbsp;
    </p>
    </th>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class align=3D"left" valign=3D"top" height=3D"12" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; font-size: 12px; line-height: 12px; font-family: Aria=
l, Helvetica, sans-serif; color: #58595B; padding: 0px 0px 0px 0px; backgro=
und-color: #ffffff;" bgcolor=3D"#ffffff">
    &nbsp;</td>
    </tr>
    </tbody>
    </table>
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell body_copy" align=3D"left" valign=3D"top"=
 style=3D"mso-hyphenate: none; width: 600px; padding: 0px 0px 0px 0px; word=
-break: break-word; font-weight: normal;" width=3D"600">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 14px; line-height: 22px; text-align: center; color=
: #58595B; margin: 0;">
    &nbsp;
    <a href=3D"#" target=3D"_blank" style=3D"word-break: break-word; mso-hy=
phenate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; =
text-decoration: none;"><strong style=3D"word-break: break-word; mso-hyphen=
ate: none; font-family: Arial,  Helvetica,  sans-serif; color: #006ead;"><u=
 style=3D"word-break: break-word; mso-hyphenate: none;">Learn
    About Merck
    Oncology Patient Support</u></strong><strong style=3D"word-break: break=
-word; mso-hyphenate: none; font-family: Arial,  Helvetica,  sans-serif; co=
lor: #006ead;">
    &#00062;</strong></a>&nbsp;
    </p>
    </th>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>


<tr style=3D"word-break: break-word; mso-hyphenate: none;">
<td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphenate=
: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; padding=
: 0px 0px 0px 0px;">
<table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" styl=
e=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt; ms=
o-table-rspace: 0pt;">
<tbody style=3D"word-break: break-word; mso-hyphenate: none;">
<tr style=3D"word-break: break-word; mso-hyphenate: none;"><th class=3D"dev=
ice_width spacer" style=3D"word-break: break-word; mso-hyphenate: none; fon=
t-weight: normal; height: 22px; font-size: 22px; line-height: 22px;" height=
=3D"22">&nbsp;</th></tr>
</tbody>
</table>
</td>
</tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding: 0px 0px 0px 0px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell footer" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 0px 20px; word-=
break: break-word; font-weight: normal;" width=3D"620">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 12px; line-height: 13.2px; text-align: left; color=
: #262626; margin: 0;">
    <strong style=3D"word-break: break-word; mso-hyphenate: none; font-fami=
ly: Arial,  Helvetica,  sans-serif;">For prescribers:
    please </strong><a href=3D"https://www.merckconnect.com/pricing-disclos=
ures/" target=3D"_blank" style=3D"word-break: break-word; mso-hyphenate: no=
ne; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; text-decora=
tion: none;"><strong style=3D"word-break: break-word; mso-hyphenate: none; =
font-family: Arial,  Helvetica,  sans-serif; color: #006EAD;"><u style=3D"w=
ord-break: break-word; mso-hyphenate: none;">click
    here</u></strong></a><strong style=3D"word-break: break-word; mso-hyphe=
nate: none; font-family: Arial,  Helvetica,  sans-serif;"> for
    state-required price disclosures.</strong>
    </p>
    </th>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class align=3D"left" valign=3D"top" height=3D"12" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; font-size: 12px; line-height: 12px; font-family: Aria=
l, Helvetica, sans-serif; color: #262626; padding: 0px 0px 0px 0px; backgro=
und-color: #ffffff;" bgcolor=3D"#ffffff">
    &nbsp;</td>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; pad=
ding: 0px 0px 0px 0px;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"column__parent device_width" style=3D"word-break: break-wo=
rd; mso-hyphenate: none; width: 660px; font-weight: normal;" width=3D"660">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell footer" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 12px 20px; word=
-break: break-word; font-weight: normal;" width=3D"620">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 12px; line-height: 16px; text-align: left; color: =
#262626; margin: 0;">
    <span style=3D"word-break: break-word; mso-hyphenate: none; font-family=
: Arial,  Helvetica,  sans-serif;">Note:
    This message was
    distributed from an email account used for sending messages
    only. Please do not reply to
    this message.</span>
    </p>
    </th>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell footer" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 0px 20px; word-=
break: break-word; font-weight: normal;" width=3D"620">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 12px; line-height: 16px; text-align: left; color: =
#262626; margin: 0;">
    <span style=3D"word-break: break-word; mso-hyphenate: none; font-family=
: Arial,  Helvetica,  sans-serif;">This
    email communication is
    from Merck Sharp &#00038; Dohme LLC. Please manage your email
    preferences or unsubscribe
    anytime by clicking </span><a href=3D"#" target=3D"_blank" style=3D"wor=
d-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -=
ms-text-size-adjust: none; text-decoration: none;"><u style=3D"word-break: =
break-word; mso-hyphenate: none; font-family: Arial,  Helvetica,  sans-seri=
f; color: #006EAD;">here</u></a><span style=3D"word-break: break-word; mso-=
hyphenate: none; font-family: Arial,  Helvetica,  sans-serif;">. If
    you have trouble accessing
    this link, please send an email to </span><a href=3D"mailto:merck_priva=
cy_office@merck.com?subject=3DEmail Opt-Out Request  %%=3Dv(@compkey)=3D%%"=
 style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-ad=
just: none; -ms-text-size-adjust: none; text-decoration: none;"><u style=3D=
"word-break: break-word; mso-hyphenate: none; font-family: Arial,  Helvetic=
a,  sans-serif; color: #006EAD;">merck_privacy_office@merck.com</u></a><spa=
n style=3D"word-break: break-word; mso-hyphenate: none; font-family: Arial,=
  Helvetica,  sans-serif;"> with a
    subject line of Email Opt-Out Request &#08211; US&zwj;-&zwj;PDS&zwj;-&z=
wj;00&zwj;02&zwj;4.</span>
    </p>
    </th>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class align=3D"left" valign=3D"top" height=3D"12" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; font-size: 12px; line-height: 12px; font-family: Aria=
l, Helvetica, sans-serif; color: #58595B; padding: 0px 0px 0px 0px; backgro=
und-color: #ffffff;" bgcolor=3D"#ffffff">
    &nbsp;</td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell footer" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 12px 20px; word=
-break: break-word; font-weight: normal;" width=3D"620">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 12px; line-height: 16px; text-align: left; color: =
#262626; margin: 0;">
    <span style=3D"word-break: break-word; mso-hyphenate: none; font-family=
: Arial,  Helvetica,  sans-serif;">Copyright
    &#00169; 2025 Merck &#00038;
    Co., Inc., Rahway, NJ, USA and its affiliates. All rights
    reserved.</span>
    </p>
    </th>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell footer" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 0px 20px; word-=
break: break-word; font-weight: normal;" width=3D"620">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 12px; line-height: 16px; text-align: left; color: =
#262626; margin: 0;">
    <span style=3D"word-break: break-word; mso-hyphenate: none; font-family=
: Arial,  Helvetica,  sans-serif;">To
    learn more about Merck&#08217;s
    commitment to privacy and your rights, please visit
    </span><a href=3D"https://www.msdprivacy.com/us/en/" target=3D"_blank" =
style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adj=
ust: none; -ms-text-size-adjust: none; text-decoration: none;"><u style=3D"=
word-break: break-word; mso-hyphenate: none; font-family: Arial,  Helvetica=
,  sans-serif; color: #006EAD;">merck.com/privacy</u></a><span style=3D"wor=
d-break: break-word; mso-hyphenate: none; font-family: Arial,  Helvetica,  =
sans-serif;">.</span>
    </p>
    </th>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class align=3D"left" valign=3D"top" height=3D"12" style=3D"word-bre=
ak: break-word; mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-te=
xt-size-adjust: none; font-size: 12px; line-height: 12px; font-family: Aria=
l, Helvetica, sans-serif; color: #262626; padding: 0px 0px 0px 0px; backgro=
und-color: #ffffff;" bgcolor=3D"#ffffff">
    &nbsp;</td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <th class=3D"device_width cell footer" align=3D"left" valign=3D"top" st=
yle=3D"mso-hyphenate: none; width: 620px; padding: 0px 20px 20px 20px; word=
-break: break-word; font-weight: normal;" width=3D"620">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 12px; line-height: 16px; text-align: left; color: =
#262626; margin: 0;">
    <span style=3D"word-break: break-word; mso-hyphenate: none; font-family=
: Arial,  Helvetica,  sans-serif;">Merck Privacy Office, 351 N Sumneytown P=
ike, UG4B-24, North Wales, PA 19454, USA</span>
    </p>
    </th>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"layout columns" style=3D"word-break: break-word; mso-hyphe=
nate: none; -webkit-text-size-adjust: none; -ms-text-size-adjust: none;">
    <table width=3D"100%" cellspacing=3D"0" cellpadding=3D"0" border=3D"0" =
style=3D"word-break: break-word; mso-hyphenate: none; mso-table-lspace: 0pt=
; mso-table-rspace: 0pt;">
    <tbody style=3D"word-break: break-word; mso-hyphenate: none;">
    <tr style=3D"word-break: break-word; mso-hyphenate: none;">
    <td class=3D"cell" align=3D"left" valign=3D"center" height=3D"46" style=
=3D"mso-hyphenate: none; -webkit-text-size-adjust: none; -ms-text-size-adju=
st: none; width: 295px; height: 46px; padding: 12px 20px 30px 20px; word-br=
eak: break-word; font-weight: normal; box-sizing: border-box;" width=3D"295=
">
    <p style=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-s=
ize-adjust: none; -ms-text-size-adjust: none; font-family: Arial, Helvetica=
, sans-serif; font-size: 12px; line-height: 16px; text-align: left; color: =
#262626; margin: 0;">
    <span style=3D"word-break: break-word; mso-hyphenate: none; font-family=
: Arial,  Helvetica,  sans-serif;">US&zwj;-&zwj;PDS&zwj;-&zwj;0&zwj;00&zwj;=
24&nbsp;10&zwj;/&zwj;25</span></p>
    </td>
    <td class=3D"cell image mobile_settings mobile__align--right mobile__va=
lign--middle isNested" align=3D"right" valign=3D"middle" height=3D"46" styl=
e=3D"word-break: break-word; mso-hyphenate: none; -webkit-text-size-adjust:=
 none; -ms-text-size-adjust: none; width: 335px; height: 46px; padding: 0px=
 20px 20px 20px; box-sizing: border-box; max-width: 100%;" width=3D"335">
    <img class=3D"desktop_img" src=3D"https://www.us-hh.com/Email/Keytruda/=
US-PDS-00024/Merck_Logo.png" title=3D"Merck Logo" alt=3D"Merck Logo" width=
=3D"110" border=3D"0" style=3D"word-break: break-word; mso-hyphenate: none;=
 border: 0; display: block; max-width: 100%; color: #58595B; font-size: 7px=
; line-height: 7px;">
    </td>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>
    </tbody>
    </table>
    </center>
    </td>
    </tr>
    </tbody>
    </table>
    <div id=3D"_two50" style=3D"word-break: break-word; mso-hyphenate: none=
; -webkit-text-size-adjust: none; -ms-text-size-adjust: none;"></div> <img =
id=3D"_two50_img" src=3D"https://2merck.everestengagement.com/ea/rL7XYGpnkw=
/?e=3D%%_SubscriberKey%%&c=3D%%=3Dv(@compkey)=3D%%" width=3D"1" height=3D"1=
" style=3D"word-break: break-word; mso-hyphenate: none; margin: 0; padding:=
 0; border: 0; height: 1px; width: 1px;">
   =20
  <div align=3D"center" style=3D"background-color: #F3F3F3;"><table width=
=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D"0" style=3D"backgro=
und-color: #f3f3f3"><tr><td align=3D"center" valign=3D"top" style=3D"paddin=
g: 0px 0px 0px 0px;"><div align=3D"center" style=3D"max-width: 600px; margi=
n-left: auto; margin-right: auto;"><table cellpadding=3D"0" cellspacing=3D"=
0" border=3D"0" style=3D"width: 600px; width: auto !important; margin-left:=
 auto; margin-right: auto;"><tr><td align=3D"left" valign=3D"top" style=3D"=
color: #5b5b5b; font-size: 11px; line-height: 1.3; font-family: Arial, Helv=
etica, sans-serif; padding: 20px 20px 20px 20px;"><div style=3D"color: #FF0=
000; font-size: 11px; line-height: 1.3; font-family: Arial, Helvetica, sans=
-serif;"><span style=3D"font-size: 13px; font-weight: bold;">THIS IS A TEST=
 EMAIL ONLY.</span><br />This email was sent by the author for the sole pur=
pose of testing a draft message. If you believe you have received the messa=
ge in error, please contact the author by replying to this message. Constan=
t Contact takes reports of abuse very seriously. If you wish to report abus=
e, please forward this message to <a href=3D"mailto:abuse@constantcontact.c=
om">abuse@constantcontact.com</a>.<br /></div></td></tr></table></div></td>=
</tr></table></div></body>



=09</html><table class=3D"footer-container" width=3D"100%" cellpadding=3D"0=
" cellspacing=3D"0" border=3D"0" style=3D"background: #ffffff; margin-left:=
 auto; margin-right: auto; table-layout: auto !important" bgcolor=3D"#fffff=
f">
  <tr>
    <td width=3D"100%" align=3D"center" valign=3D"top" style=3D"width: 100%=
;">
      <div class=3D"footer-max-main-width" align=3D"center" style=3D"margin=
-left: auto; margin-right: auto; max-width: 100%;">
        <table width=3D"100%" cellpadding=3D"0" cellspacing=3D"0" border=3D=
"0">
          <tr>
            <td class=3D"footer-layout" align=3D"center" valign=3D"top" sty=
le=3D"padding: 16px 0px;">
              <table class=3D"footer-main-width" style=3D"width: 580px;" bo=
rder=3D"0" cellpadding=3D"0" cellspacing=3D"0">
                <tr>
                  <td class=3D"footer-text" align=3D"center" valign=3D"top"=
 style=3D"color: #5d5d5d; font-family: Verdana,Geneva,sans-serif; font-size=
: 12px; padding: 4px 0px;">
                   =20
                    <span class=3D"footer-column">MD Newsline<span class=3D=
"footer-mobile-hidden"> | </span></span><span class=3D"footer-column">222 W=
 Merchandise Mart Plaza<span class=3D"footer-mobile-hidden">, </span></span=
><span class=3D"footer-column">#1212<span class=3D"footer-mobile-hidden">, =
</span></span><span class=3D"footer-column"></span><span class=3D"footer-co=
lumn">Chicago, IL 60654</span><span class=3D"footer-column"></span>
                   =20
                  </td>
                </tr>
                <tr>
                  <td class=3D"footer-row" align=3D"center" valign=3D"top" =
style=3D"padding: 10px 0px;">
                    <table cellpadding=3D"0" cellspacing=3D"0" border=3D"0"=
>
                      <tr>
                        <td class=3D"footer-text" align=3D"center" valign=
=3D"top" style=3D"color: #5d5d5d; font-family: Verdana,Geneva,sans-serif; f=
ont-size: 12px; padding: 4px 0px;">
                          <a href=3D"#" style=3D"color: #5d5d5d">Unsubscrib=
e</a>
                        </td>
                      </tr>
                      <tr>
                        <td class=3D"footer-text" align=3D"center" valign=
=3D"top" style=3D"color: #5d5d5d; font-family: Verdana,Geneva,sans-serif; f=
ont-size: 12px; padding: 4px 0px;">
                          <a href=3D"#" style=3D"color: #5d5d5d">Update Pro=
file</a> |
                         =20
                          <a class=3D"footer-about-provider" href=3D"https:=
//www.constantcontact.com/legal/customer-contact-data-notice" style=3D"colo=
r: #5d5d5d">Constant Contact Data Notice</a>
                        </td>
                      </tr>
                      <tr>
                        <td class=3D"footer-text" align=3D"center" valign=
=3D"top" style=3D"color: #5d5d5d; font-family: Verdana,Geneva,sans-serif; f=
ont-size: 12px; padding: 4px 0px;">
                          Sent by
                         =20
                          <a href=3D"mailto:info@mdnewsline.com" style=3D"c=
olor: #5d5d5d; text-decoration: none">info@mdnewsline.com</a>
                         =20

                         =20
                         =20
                          <span class=3D"footer-column">powered by</span>
                         =20
                         =20
                        </td>
                      </tr>
                    </table>
                  </td>
                </tr>
                <tr>
                  <td class=3D"footer-text" align=3D"center" valign=3D"top"=
 style=3D"color: #5d5d5d; font-family: Verdana,Geneva,sans-serif; font-size=
: 12px; padding: 4px 0px;">
                   =20
                   =20
                    <a href=3D"https://www.constantcontact.com/landing1/vr/=
home?cc=3Dnge&utm_campaign=3Dnge&rmc=3DVF21_ACE&utm_medium=3DVF21_ACE&utm_s=
ource=3Dviral&pn=3DROVING&nav=3D029d396b-afcd-4ccc-92aa-afdc3349aff9" style=
=3D"color: #5d5d5d; text-decoration: none">
                    <img alt=3D"Trusted Email from Constant Contact - Try i=
t FREE today." width=3D"160" border=3D"0" hspace=3D"0" vspace=3D"0" src=3D"=
https://static.ctctcdn.com/letters/images/CTCTFooter/Logo_Blue_Orange_2022.=
png">
                    </a>
                    <div class=3D"footer-cta-text" style=3D"color: #5d5d5d;=
 font-family: Verdana,Geneva,sans-serif; font-size: 9px; line-height: 2">
                    <a href=3D"https://www.constantcontact.com/landing1/vr/=
home?cc=3Dnge&utm_campaign=3Dnge&rmc=3DVF21_ACE&utm_medium=3DVF21_ACE&utm_s=
ource=3Dviral&pn=3DROVING&nav=3D029d396b-afcd-4ccc-92aa-afdc3349aff9" style=
=3D"color: #5d5d5d; text-decoration: none">Try email marketing for free tod=
ay!</a>
                    </div>
                   =20
                   =20
                  </td>
                </tr>
              </table>
            </td>
          </tr>
        </table>
      </div>
    </td>
  </tr>
</table></body></html>
------=_Part_79869416_238998003.1760366274476--
